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Structure-based Design of Small Molecule Inhibitors of HIV-1 Entry 
Matthew Le-Khac 
 
 HIV infection begins when gp120 envelope protein on the viral surface binds to the CD4 
receptor on the host cell.  This initial protein-protein interaction starts the rest of the HIV 
lifecycle of coreceptor binding, fusion and replication.  One of the targets of HIV entry inhibitors 
is the interaction between CD4 and gp120.  A large percentage of CD4-gp120 contacts revolved 
around a cavity in gp120 in which the PHE43 residue of CD4 caps.   
  We were able to design and synthesize a progression of small molecule compounds 
targeting the PHE43CD4 cavity in gp120 based on a previous CD4-mimetic, NBD-556.  By either 
soaking or co-crystallizing the newly designed compounds bound to gp120, we were able to 
solve four x-ray crystal structures in order to observe the interactions with the binding cavity on 
the atomic level.  Using x-ray crystal structure, isothermal calorimetry and viral binding assay to 
guide design, we were able to improve the binding affinity more than 30 fold compared to the 
original NBD-556.  Our most potent compound DMJ-II-121-R,R is able to bind to gp120 at a Kd 
of 0.11 µM and specifically block HIV-1 entry at an IC50 of 2.3 µM.  Along with improved 
potency, the new design alleviated the agonistic properties of the original NBD-556, which was 
inducing gp120 to bind to the coreceptors on the host cell instead of blocking the progression of 
the HIV lifecycle.   
 In parallel, we also utilized the soakable gp120 crystal system to screen a library of 352 
fragments of various shapes using x-ray crystallography to detect and identify two positive hits, 
benzimidazole and 3-hydroxyphenylacetic acid. The possible leads from the two identified 
fragments along with our improved potency of NBD-556 based derivatives offer valuable insight 
to guide us on the development toward a subnanomolar small molecular antagonist of gp120-
CD4 binding.  
!
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Introduction: The mechanism of HIV-1 life cycle and 
the therapeutics targeting them 
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We are entering the fourth decade of the AIDS epidemic. The understanding of acquired 
immunodeficiency syndrome (AIDS) has made remarkable progress since the first discovery of 
the human immunodeficiency virus (HIV-1) causing the devastating disease (Barre-Sinoussi et 
al, 1983; Gallo et al, 1984). An estimate of 33.3 million adult and children in the world are HIV-
positive--with around 2.6 million new infection cases and 1.8 million deaths caused by the virus 
each year (UNAIDS, 2010). Doctors now have approximately 30 antiretroviral drugs at their 
disposal to treat patients diagnosed with AIDS (Broder, 2010).  The available drugs target 
several distinct stages of the HIV replication cycle 
Attacking ability of the virus to replicate does not completely eliminate the infection but 
merely suppresses the virus levels in the patient’s plasma (Chun et al, 1997; Finzi et al, 1997; 
Wong et al, 1997). Latent reservoirs of the remaining virus commit the patient to a life term of 
antiretroviral treatment to prevent the reemergence of the disease (Chun et al, 1999).  Although 
current HIV antiretroviral therapeutics contributed to a 19% decline in HIV-related mortality 
between 2004 and 2009, hurdles in the form of drug-resistant strains, adverse drug-drug 
interactions and life-long drug obligation leave room for improvement and the field in search of 
other possible therapeutic targets (Jimenez-Nacher et al, 1998; Boden et al, 1999; Lucas et al, 
1999; Yerly et al, 1999; UNAIDS, 2010). 
 One appealing target for novel drug design involves the preliminary entry of HIV-1 into 
the host cell. Targeting the entry stage of the HIV life cycle allows not only for treatment but for 
the possibility of prevention as well.  Since entry inhibitors deal with mechanisms in the exterior 
of the cell, their accessibility is more appealing than the therapeutics aimed at the viral 
replication involved in the interior of the host cell.  Current entry inhibitors follow a range of 
different strategies that take advantage of the intricate, multistep nature that the virus undertakes 
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to invade the host cell.  Although entry involves multiple stages, the entire process utilizes only 
two viral envelope (Env) glycoproteins: gp120 and gp41.  
 
HIV Envelope Glycoproteins: The viral tools of entry 
The only viral proteins on HIV exposed outside of the virion membrane are gp120 and 
gp41; thus allowing potential therapeutics to target the virus before it even enters the host cell.  
Existing as pairs, gp120 and gp41 originate from the furin-mediated cleavage of their precursor 
glycoprotein: gp160 (Allan et al, 1985; Hallenberger et al, 1992). The more exterior and exposed 
subunit of the group, gp120 pairs with gp41 through non-covalent interactions while gp41 itself 
is anchored as a transmembrane component in the virion lipid bilayer (Helseth et al, 1991).  
These pairs of gp120/gp41 form trimers on the surface of HIV (Chan et al, 1997; Tan et al, 1997; 
Weissenhorn et al, 1997).  
 
 
Figure 1 // Ribbon diagram of gp120 conserved residues, CD4-binding site and domains. A.gp120 in CD4-
binding conformation with variable regions in red, conserved regions in white and residues involved in CD4 binding 
in yellow. B. Same as in A but with heavily glycosylated outer domain in blue, flexible gp41binding inner domain in 
white and bridging sheet in red. Both figures prepared with CHIMERA (Pettersen et al, 2004) based on PDB ID: 
3TIH. 
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The subunit of gp120 consists of five conserved regions (C1 – C5) and five variable 
regions (V1-V5) (Starcich et al, 1986; Leonard et al, 1990). The conserved domains contained 
the critical regions for host cell binding while the variable domains are found on the surface of 
gp120 in the form of exposed loops anchored by disulfide bonds at their bases in the case of V1-
V4 (Figure 1A) (Starcich et al, 1986).  Upon binding to the host cell, gp120 conforms into three 
domain motifs: a heavily glycosylated outer domain, a flexible gp-41-binding inner domain and a 
bridging sheet (Figure 1B) (Kwong et al, 1998; Kwong et al, 2000; Chen et al, 2005; Huang et al, 
2005).  With much of its exposed region either heavily glycosylated or highly variable, gp120 
has a powerful repertoire for evading the body’s natural immune defense. 
 
CD4 and gp120: The binding interactions of PHE43CD4 
 The preferred host cells for HIV are immune cells, specifically T-lymphocytes and 
macrophages, due to their surface expression of CD4: the natural ligand of gp120 (Dalgleish et 
al, 1984; Klatzmann et al, 1984).  The ability of the virus to utilize CD4 to invade immune cells 
explains its connection to immunodeficiency.  The binding interaction of CD4 takes place at a 
highly conserved, recessed region on gp120 that is devoid of gylcosylation sites that the virus 
uses to mask its antigenic sites from immune recognition (Kwong et al, 1998; Vigerust & 
Shepherd, 2007).  Crystal structure comparisons show that this recessed binding region is 
structurally conserved in CD4-bound gp120 across three different gp120 HIV isolates: YU2, 
HXBc2, JR-FL (Kwong et al, 1998; Kwong et al, 2000; Huang et al, 2005). On the CD4 side, the 
region responsible for gp120 interaction are 22 residues on the D1 domain—specifically a beta-
hairpin called the CDR2-like loop due to its resemblance to the second complimentarily-
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determining region in immunoglobulins (Sweet et al, 1991; Moebius et al, 1992; Kwong et al, 
1998).  The combination of conserved residues and the lack of glycosylation make an appealing 
target for entry inhibitors. 
The recessed binding site on gp120 contains a deep hydrophobic cavity.  The PHE43CD4 
residue contained on the CDR2-like loop beta hairpin of CD4 sits at the opening of the gp120 
cavity and essentially plugs it during CD4-gp120 binding. Since PHE43CD4 is the only residue on 
CD4 that interacts with the cavity, it received the moniker “PHE43CD4 cavity” (Kwong et al, 
1998; Kwong et al, 2000).  The PHE43CD4 residue alone accounts for 23% of the CD4-gp120 
interatomic contacts but most of the interactions are limited around the lip of the cavity since the 
only atom of the PHE43CD4 that interacts with the cavity is the Cζ.  Thus the CD4 binding site on 
gp120 can be divided into two distinct regions: the PHE43CD4 cavity and the vestibule 
immediately surrounding the cavity.  The inner domain, outer domain and bridging sheet all 
contribute residues that form the cavity and vestibule for CD4 binding.   
 
Gp120: the CD4 bound and unliganded states 
Binding to CD4 induces gp120 to undergo a substantial structural rearrangement that 
results in the formation of the coreceptor binding site that is needed for the second step of HIV-
entry (Figure 2A).  The outer domain remains relatively the same but the inner domain 
substructures undergo a series of displacements and two sets of beta-strands come together to 
form the bridging sheet (Kwong et al, 1998; Chen et al, 2005).  Thermodynamic studies show the 
binding of CD4 to gp120 causes a hugely favorable binding enthalpy--demonstrating the 
formation of numerous hydrogen bonds and van der Waals interactions--but a largely 
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unfavorable entropic change--representing the loss of degrees of freedom (Myszka et al, 2000).  
Essentially, free gp120 is very flexible but becomes more rigid upon binding to CD4. Ultimately, 
these structural changes cause the extension and exposure of V1/V2 and V3 loops and orients the 
newly formed bridging sheet and V3 loop towards the host cell membrane in preparation for the 
second stage of HIV entry: the coreceptor (Trkola et al, 1996; Wu et al, 1996; Huang et al, 
2005). 
 
CCR5 and CXCR4: The coreceptors for entry 
 Thanks to the prerequisite of CD4 binding, gp120 reveals its co-receptor binding site only 
in extreme close proximity to the host cell—another evasive feature that the virion uses to 
minimize exposure of antigenic sites to immune recognition (Figure 2B).  The primary HIV co-
receptors in humans are the chemokine receptors: CCR5 and CXCR4 (Alkhatib et al, 1996; Choe 
et al, 1996; Deng et al, 1996; Doranz et al, 1996; Dragic et al, 1996; Feng et al, 1996; Oberlin et 
al, 1996).  The two chemokine receptors are members of the G protein-coupled receptors 
(GPCR) family and have seven transmembrane helixes.  HIV-1 strains can be categorized into 
two subtypes based on their preference of chemokine receptor: M-tropic strains use CCR5 and T-
tropic strains use CXCR4.  M-tropic strains using CCR5 are more common in newly infected 
patients while T-tropic strains emerge in later stages of the disease (Clapham & McKnight, 
2002).  On both chemokine receptors, the N terminus and three extracellular loops (ECL) form a 
small pocket that interacts with gp120.  Sulfated tyrosines on the N terminus and the second ECL 
are critical in gp120 binding (Atchison et al, 1996; Rucker et al, 1996; Edinger et al, 1997). 
Specifically, the N terminus interacts with the base of the V3 loop and bridging sheet while the 
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second ECL interacts with the tip of the V3 loop (Hoffman et al, 1999; Cormier et al, 2001; 
Basmaciogullari et al, 2002; Cormier & Dragic, 2002; Huang et al, 2007). 
 
Gp41: The mediator of fusion 
!
Figure 2 // HIV-1 entry into host cell. A. gp120 binds to CD4 inducing gp120 to reveal coreceptor (CR) binding 
site . B. gp120 binds either CCR5 or CXCR4 coreceptors C. Conformational changes induces gp41 to insert its 
hydrophobic region into the host cell membrane D. gp41 folds into a six-helix bundle bringing the virion membrane 
close enough for fusion with the host membrane. Figure provided by W. A. Hendrickson. 
 
The binding of coreceptor to gp120 triggers further structural changes in the envelope 
trimer that expose the hydrophobic region of gp41 responsible for membrane fusion and insert its 
N-terminal fusion peptide into the host cell lipid bilayer (Figure 2C).  Following the insertion, 
gp41 undergoes a highly favorable energetic conformational change causing gp41 to fold into a 
six-helix bundle--bringing the viral membrane in close enough proximity to form a fusion pore 
with the host membrane (Figure 2D) (Chan et al, 1997; Weissenhorn et al, 1997). However, 
recent evidence has implied full fusion may not occur at the host cell surface but after the virion 
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particle has been brought into the cell through endocytosis upon binding to the coreceptor 
(Miyauchi et al, 2009).  
 
HIV-Replication: Integration into the host chromosome 
!
Figure 3 // Six steps of HIV-1 life cycle. 1) Viral Entry mediated by gp120 and gp41; 2) Reverse transcription of 
viral RNA into DNA mediated by reverse transcriptase (RT); 3) Integration of viral DNA into host cell genome 
mediated by integrase (IT); 4) Transcription of viral mRNA and translation into poly-proteins; 5) Packaging and 
budding of virion; 6) Maturation of virion, primed for host cell entry. PR=protease. Adapted from figure provided 
by W. A. Hendrickson. 
 
 Upon successful host cell entry, HIV uses a repertoire of other proteins besides gp120 
and gp41 to accomplish replication and maturation: the later stages of the HIV life cycle (Figure 
3).  Besides gp120 and gp41, HIV-1 has four Gag proteins (matrix, capsid, nucleocapsid, p6), 
three Pol proteins (protease, reverse transcriptase, integrase) and six accessory proteins (Vif, 
Vpr, Nef, Tat, Rev, Vpu). After entry, the virus uses reverse transcriptase to reverse-transcribe its 
RNA genome into DNA for incorporation into the host cell genome.  Upon successful transport 
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of the virus DNA into the host cell nucleus, integrase catalyzes the integration of the virus DNA 
into the host cell genome.  Unspliced and spliced viral mRNA are synthesized from the virally 
co-opted host cell genome and transported to the cytoplasm where they can be translated into 
long uncleaved peptide chains containing multiple viral proteins called viral poly-proteins. These 
viral poly-proteins--along with furin-cleaved gp120 and gp41--make up the virion core particle 
with unspliced viral genome length mRNA. The virion core particles emerged from the host cell 
membrane as buds and once released, the virus finishes its maturation by cleaving the viral poly-
protein with HIV protease marking the end of the last stage in the cycle while allowing a newly-
generated viruses to begin the HIV life cycle a new (Frankel & Young, 1998).   
 
Antiretroviral Therapy: The road to a cure  
 The majority of the therapeutics available to HIV-1 patients target viral replication and 
maturation.  Nucleoside, non-nucleoside and nucleotide inhibitors are reverse transcriptase 
inhibitors that prevent HIV replication. Protease inhibitors prevent the maturation of the newly 
budded HIV virion particles from maturing.  The very first HIV drugs were nucleoside reverse 
transcriptase inhibitors (NRTIs) designed to prevent HIV transcription in the host cell by 
competitively binding to the viral reverse transcriptase (Broder, 1990).  Nucleotide inhibitors 
(NtRTIs) work in the same competitive manner while non-nucleoside inhibitors (NNRTIs) target 
an allosteric binding site distinct from the reverse transcriptase catalytic site.  If reverse 
transcription does occur, there are two types of thereupeutics that block intergration of the viral 
DNA into the host cell genome.  The first more, broader inhibitor is an intergrase inhibitor (INI), 
which seeks to prevent the intergrase from complexing to the viral DNA.  The second, more 
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specific and successful therapeutic is intergrase strand transfer inhibitor (InSTI) which only 
binds after the intergrase has complexed with the viral DNA and prevent the process from 
completing--leading to a irreversible block to this rate limiting step (Hazuda, 2012).  On the 
other hand, protease inhibitors bind competitively at the substrate site of HIV-1 protease and 
prevent the virus from cleaving the viral polypeptides needed in its maturation stage. The 
majority of the 30 antiviral drugs available for HIV treatment currently ranges within these 
categories of viral replication and maturation targeting.  Due to the high mutation and fast 
replication rates (every 48hrs), drug resistant strains of the virus emerge rapidly especially in the 
case of monotheraphy when a single antiretroviral drug is taken for treatment.  In order to 
combat these mutational rates, the field has produced highly active antiretroviral therapy 
(HAART)--a regimen of at least three different protease and reverse transcriptase inhibitors 
(Broder, 2010).  Despite the success of HAART, the inability to completely suppress latent 
reservoirs of the virus, susceptibility to drug resistant strains and drug toxicity still leave room 
for substantial improvement.   
 
Vaccines: Invisible to the Immune system 
 HIV-1 gp120 manages to elude normal humoral immunity by hiding behind a cloak of 
glycosylated moieties covering its outer domain, keeping its exposed loops highly variable and 
never showing its conserved receptor binding site until absolutely necessary through its 
conformational flexibility (Starcich et al, 1986; Wyatt et al, 1998; Myszka et al, 2000; Wei et al, 
2003).  The high mutability and genetic diversity of HIV-1 causes a plethora of ever changing 
antigens that overwhelms the immune system.   The first vaccine efficacy-trial used two 
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recombinant gp120 antigens derived from clade B strains to no avail (Flynn et al, 2005).  The 
first major efficacy trial to show at least a proof of principle that a vaccine can reduce infection 
rate used ALVAC, a live recombinant viral vector, and coupled it with a protein-based booster 
vaccine called AIDSVAX resulting in reports of 31% reduction in infectivity (Rerks-Ngarm et 
al, 2009). The latest major effort in vaccine development utilizes VRC01, an antibody that binds 
directly with the highly conserved and exposed CD4-binding site on the viral gp120 as shown in 
its crystal structure (Zhou et al, 2010). Considering the antibody binds at a highly conserved site, 
VRC01 demonstrates a wide breadth in reactivity: neutralizing more than 90% of naturally 
circulating world strains (Wu et al, 2010).  However potent the VRC01 antibody can be, the 
average natural gestation process of several years to produce the antibody in HIV-1 infected 
patients is too lengthy for effective treatment.   Current studies are trying to design recombinant 
gp120 that have strong affinity to immune cells expressing early precursors of VRC01 to 
hopefully increase the efficiency of the induction and maturation process of these potent 
antibodies (Kwong et al, 2012). 
 
Entry inhibitor: A potential preventative and treatment 
 In contrast to vaccine-induced antibodies targeting the viral Env, novel forms of 
therapeutics are emerging from the field in forms of entry inhibitors targeting the three stages of 
HIV entry: gp41-driven fusion, gp120-coreceptor binding and gp120-CD4 binding.  HIV entry is 
an attractive target due to the fact that the entry mechanisms occur on the exterior of the cell 
allowing better drug accessibility; also, the entry stage of the HIV life cycle occurs before host 
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cell infection and the proliferation of the virus.  Both reasons allow for the possibility of a 
therapeutic that is both preventive and a therapeutic.  
 The first FDA-approved entry inhibitor and the only one targeting gp41-fusion is 
enfuvirtide (Wild et al, 1992; Jiang et al, 1993).  The fusion inhibitor enfuvirtide is a synthetic 
linear peptide composed of 36 amino acids identical to a region in the HR2 domain (Wild et al, 
1993).  By competing against HR2 to bind with HR1, enfuvirtide has shown potency in clinical 
trials but has faltered with ranging effectiveness depending on the strain of virus (Derdeyn et al, 
2000; Kilby et al, 2002; Reeves et al, 2002; Lalezari et al, 2003; Melby et al, 2006). Initial 
evidence has shown that the binding region for the enfuvirtide reveals itself in the HR1 domain 
of gp41 only after the viral Env protein binds to CD4—thus the fusion inhibitor prevents the 
formation of the six helix bundle and the closing of the gap between the viral and host membrane 
for fusion process (Wild et al, 1994; Chan et al, 1997; Weissenhorn et al, 1997; Reeves et al, 
2002).  An orally delivered fusion inhibitor has yet to be achieved—limiting all gp41 inhibitors 
to be delivered via injection only.  In the case of enfuvirtide, the act of oral ingestion will expose 
the peptide-based drug to rapid metabolic break down by peptidases contained in the gastro-
intestinal system (Greenberg et al, 2004).  An orally bioavailable small molecule inhibitor of 
gp41 still remains a goal for therapeutics targeting gp41.  
 Another stratagem for entry inhibitors is targeting the gp120-coreceptor binding 
interaction.  Shortly after the discovery of involvement CCR5 and CXCR4 in HIV-1 entry, the 
field discovered a naturally occurring Δ32 deletion in CCR5 carried homozygously in ~10% of 
the Caucasian that grants the carrier high-levels of immunity to HIV-1 infection (Dean et al, 
1996; Liu et al, 1996; Samson et al, 1996). The findings demonstrated that blocking the gp120-
CCR5 binding could be an effective as well as tolerated method of treatment strategy.  A 
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derivative of the natural ligand of CCR5, RANTES, is currently in development as a possible 
microbicide and competitive antagonist of gp120-coreceptor binding (Lederman et al, 2004; 
Cerini et al, 2008; Gaertner et al, 2008).  Maraviroc (UK-427857) is a FDA-approved small 
molecule CCR5 antagonist taken orally twice a day to treat patients infected with HIV strains 
that are resistant to antiretroviral therapeutics (Boesecke & Pett, 2012).  Antibodies have also 
been developed to prevent gp120-coreceptor binding; a prominent example is PRO-140—a 
humanized mouse antibody that prevents gp120 binding to CCR5 while still allowing natural 
ligand activity (Trkola et al, 2001; Jacobson et al, 2008).  Designing an entry inhibitor for 
CXCR4 proves a bit more problematic due to the fact that CXCR4 is essential to several 
physiological processes.  In humans for example, heterozygous mutations that truncate the 
cytoplasmic tail of CXCR4 cause WHIM syndrome—an immunodeficiency disease (Hernandez 
et al, 2003).  The bicyclam analog known as AMD-3100 showed potent activity against CXCR4-
utilizing T-tropic HIV strains in vitro but clinical trials were stopped short due to its inability to 
reduced significant viral load and its induction of cardiac abnormalities (Hendrix et al, 2004). 
 
CD4-mimetics: Inhibiting gp120-CD4 binding 
 The first trailblazing therapeutic to focus on gp120-CD4 inhibition was a soluble version 
of the cell-associated CD4 called sCD4.  Essentially composed of just the extracellular domain 
of CD4, sCD4 inhibited HIV entry by competitively binding in vitro with gp120 at a 
disassociation constant (Kd) of 2 nM compared to a Kd of 5 nM for natural cell-associated CD4 
(Schnittman et al, 1988; Martin et al, 2003).  However, sufficient levels could not be obtained to 
reproduce the effect in clinical patients (Daar et al, 1990).  The short plasma half-life of 45 
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minutes may explain the failure of the inhibition ability of sCD4 in vivo (Schooley et al, 1990).   
Despite this setback, sCD4 provided the foundational motif for the majority of gp120-CD4 
therapeutics that began emerging in the form of sCD4 derivatives and CD4 mimetics.  An 
example of sCD4 derivative, PRO-542 CD-IgG2 tetrameric fusion peptide combines elements 
from both CD4 domains and human immunoglobulin for multivalency (Allaway et al, 1995). In 
clinical trials, PRO-542 shows promising potency but the main drawback is its need for 
intravenous delivery (Sierra-Aragon & Walter, 2012).   
  A pattern of efficiency can be seen in the evolution of CD4 mimetics. Beginning from 
foundational basis of full length natural CD4, the CD4 mimetics are becoming smaller and more 
efficient—isolating the more critical structural features of CD4 and trimming away unnecessary 
elements.  One of the major transitions occurred after the importance of the CDR2-like loop 
region of CD4 in gp120 binding was isolated; henceforth, CD4 derivatives began mimicking just 
the loop itself (Jameson et al, 1988; Scarselli et al, 1997).  However, these early efforts of just 
the CDR2-like loop bound rather poorly and exhibited little anti-viral activity.  The successor 
rounds of CD4 mimetics required the use of scaffolds to position the test fragments into binding 
position. One scaffold study used D1D2 domain of CD4 as a scaffold since multiple crystal 
structures have used this particular truncation.  In this D1D2 CD4 scaffold, the PHE43CD4 
residue—responsible for 23% of the gp120-CD4 interaction—was replaced with a cysteine 
allowing for chemoselective conjugation; this D1D2F43C recombinant CD4 essentially becomes 
a modular scaffold allowing various chemical groups to be attached and positioned at the 
PHE43CD4 cavity for binding, inhibition and crystallographic studies.  The most successful 
binding affinity (4.14nM) came from a D1D2F43C scaffold that had an aromatic group 
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mimicking the phenyl residue with the addition of a nitro group on the aromatic para- position 
(Xie et al, 2007).   
Another scaffold study transplanted critical functional features of the CDR2-like loop 
onto structurally similar scaffolds such as scorpion scyllatoxin and charybdotoxin or truncated 
versions of CD4 (Vita et al, 1999; Martin et al, 2003).  The most successful of these scorpion 
scaffold CD4 mimetics was CD4M33 carrying a biphenylalanine modulation at the PHE43CD4 
residue.  The modulation resulted in an inhibition of 7.5 nM and binds in a similar fashion to 
gp120 as natural CD4 (Martin et al, 2003).  As a means to an end, scaffold proteins provide a 
suitable screening platform due to their ability to position potential therapeutic fragments and 
chemical groups within the cavity as well as stabilize the gp120-CD4 binding interface; however, 
critical obstacles such as potential immune response and poor bioavailability hamper the hopes 
of using peptide-based drugs prophylactically in the near future. 
The progress of small molecule entry inhibitors has allowed therapeutics screenings and 
design to jettison the need for peptide scaffold.  BMS-378806 (BMS-806) and its improved 
indole derivative BMS-488043 (BMS-488) have both displayed to be highly potent small 
molecule inhibitors that can function effectively without scaffolds (Guo et al, 2003; Lin et al, 
2003; Wang et al, 2003; Wang et al, 2004; Ho et al, 2006).  The mechanism specifics of the 
BMS-molecules are still controversially understood: some studies suggest the compounds bind 
competitively the sCD4 binding site on gp120 while others suggest they have no capability of 
blocking sCD4 binding (Lin et al, 2003; Ho et al, 2006; Schon et al, 2006).  A further study 
suggests that the therapeutic interferes with the gp120-gp41 rearrangement that occurs after CD4 
successfully binds (Si et al, 2004). Thermodynamic data shows that these BMS-compounds do 
not exhibit the large negative entropy and largely favorable enthalpy changes associated with the 
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structuring and ordering of gp120 upon binding to CD4 (Si et al, 2004; Schon et al, 2006).  
Unfortunately, no crystals structures exist of BMS-bounded gp120 to clarify our understanding 
of the mechanism of inhibition and the binding site. 
 
NBD-derivatives: Small molecule CD4-mimetics 
 
 
Figure 4 // An example of NBD-Pharmacophore. Region I contains a halogenated phenyl ring, Region II contains 
an oxalamide linker, Region III contains a tetrylmethylpiperdine ring. Adapted from (LaLonde et al, 2012). 
 
In terms of CD4 mimicry, a family of derivatives based on NBD-556 and NBD-557 has 
shown binding properties more akin to CD4 than any other small molecule therapeutic tested so 
far.  The Debnath group first identified the two drug-like NBD-compounds from a library of 
33,000 using a syncytium formation assay (Zhao et al, 2005).  Mutational, thermodynamic and 
crystallographic evidence show that these NBD-derivatives bind at the PHE43CD4 cavity similar 
to natural CD4.  As seen in Figure 5, three distinct regions make up the pharmacophore of the 
foundational NBD-chemotype: region I consists of a halogentated phenyl ring; region II has an 
oxalamide linker; region III is a tetramethylpiperdine ring (Madani et al, 2008; Yamada et al, 
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2010; LaLonde et al, 2012).  Mutational studies of conserved residues in the PHE43CD4 cavity 
indicate that the binding site for the NBD-compounds does occur at this pocket; for instance, 
filling the PHE43CD4 cavity with a S375Wgp120 mutation reduces the binding effectiveness of 
NBD-556 (Schon et al, 2006; Madani et al, 2008; Lalonde et al, 2011; Schon et al, 2011).  
Crystal structures of the NBD-compounds support the mutational studies and reveal that NBD-
556 binds with region I (halogenated phenyl ring) deep in the PHE43CD4 cavity, region II (the 
oxalamide linker) traversing toward the cavity opening and region III (piperdine ring) sitting at 
the cavity vestibule (Kwon et al, 2012).  Further crystal structures of the NBD-derivatives show 
that the halogenated phenyl ring and oxalamide linker are essentially in the same positions--with 
the major structural changes only occurring at region III (LaLonde et al, 2012).  
In contrast with the BMS-entry inhibitors, NBD-compounds have the same highly 
favorable enthalpy compensated by a large unfavorable entropy pattern as seen in natural CD4 
binding thermodynamics (LaLonde et al, 2012).  The similar thermodynamic characteristics 
indicate that NBD-compounds induce an analogous structural reordering of gp120 as natural 
CD4-bound gp120.  With this considered, the inherent concern with CD4 mimetics is the 
potentiality of agonistically enhancing viral infection by inducing gp120 into its coreceptor 
binding stage.   
Observations in a (Haim et al, 2009) paper suggested that some NBD compounds 
circumnavigate their agonistic properties by inducing a short-lived coreceptor ready state in 
gp120 that spontaneously and irreversibly transitions into a non-functional conformation if it 
does not contact the appropriate coreceptor immediately. Viral inhibition assays on CD4-
positive, coreceptor-positive cells reveal that even if NBD-compounds induce gp120 into the 
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next stage of HIV life cycle, the overall viral inhibition outcompetes and neutralizes the agonistic 
properties (Madani et al, 2008; Haim et al, 2009; Lalonde et al, 2011; LaLonde et al, 2012).   
In the following work, the rational design of small molecule CD4 mimetics based on 
crystallographic structure, viral binding assays and thermodynamics have allowed for the 
significant improvement of binding and viral inhibition over their foundational precursors: NBD-
556 and NBD-557.  In parallel, crystallographic screenings of a 352-fragment library have also 
provided potential leads distinct from the chemical shape motifs that define the NBD-derivatives 












































































Structural-activity relationships of NBD-derivatives 
binding to gp120 
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Introduction 
 The recent advances of HIV-1 gp120 x-ray crystal-structure technology has relieved the 
need for scaffolds to hold gp120 in a crystallizable state as well as to position potential drug-
candidates in the PHE43CD4 cavity for structural-activity relationship (SAR) studies. Originally, 
the protein crystallization of HIV-1 gp120 for x-ray crystallographic structure determination 
required a ternary complex of gp120, an antibody fragment and CD4 (Kwong et al, 1998; Kwong 
et al, 2000; Huang et al, 2005b).  The only previous crystal structures of drug compounds in the 
PHE43CD4 cavity relied on a CD4-mimicking scaffold as well as an antibody fragment to provide 
the gp120 with enough structural rigidity to crystallize (Huang et al, 2005a; Stricher et al, 2008).  
Unfortunately, potential immune response and poor bioavailability curtail the use of peptide-
based drugs to just “a means to an end” instead of practical therapeutic.  
 With recent advances in HIV-1 crystalization technology from our collaborators at the 
Kwong lab, we are able to crystallize small molecules based on the precursor NBD-compounds 
in the PHE43CD4 cavity without the need for antibody fragments or scaffolds.  Figure 1 compares 
the sequence of previous gp120 crystallized in ternary complexes to the newer modified gp120 
that are able to crystallize unliganded.  The main modifications that allow for unliganded 
crystalization are the extension of the V3 loop for stabilization and the truncation of the V1/V2 
stem (Kwong et al, 1998; Kwon et al, 2012).   We were able to crystallize different version of 
unliganded gp120 from two HIV-1 strains: clade C1086 and clade A/E93TH057. Due to differing 
crystal packing, clade C1086 crystals were capable of small molecule soaking experiments in 
fully-grown apo crystals, while clade A/E93TH057 required the compound to be present in gp120 
from the beginning of crystalization—otherwise known as co-crystalization.  Despite this 
difference, both unliganded crystal structures of C1086 and clade A/E93TH057 surprisingly 
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crystallized in CD4-bound conformation for reason still not fully understood (Kwon et al, 2012).  
In essence, clade C1086 and clade A/E93TH057 gp120 crystallized into a CD4 binding state without 
the need of the natural ligand CD4 required by previous HIV-1 gp120 ternary structures.  The 
only other previous unliganded structure of gp120 was a SIV gp120 that crystallized in a non-
CD4 bound conformation (Chen et al, 2005).  Although perplexing, the fact that unliganded 
clade C1086 and clade A/E93TH057 gp120 crystallize in CD4-bound conformation has allowed us to 
examine small molecules based on NBD-compounds without the need for CD4 or CD4-
mimicking scaffolds to hold gp120 in this CD4-induced state.  Along with the capacity of clade 
C1086 gp120 crystals for soaking experiments, the CD4-bound crystallization state allowed us to 
soak our NBD-compounds of interest without worrying about the clade C1086 protein crystals 
shattering due to the drug-induced transition into CD4-bound conformation since the gp120 is 
already in this bound state.  
 The following chapter presents three NBD-derivative x-ray crystal structures determined 
by soaking experiments in clade C1086 gp120 and one by co-crystallization with clade A/E93TH057.  
The information from these crystal structures allowed us to isolate more potent enantiomers, 
explain peculiar binding characteristics and guide optimization of NBD-derivatives bound in the 
PHE43CD4 cavity. 
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93TH057      VWKDADTTLFCASDAKAHETEVHNVWATHACVPTDPNPQEIHLENVTENFNMWKNNMVEQ 
C1086        VWKEAKTTLFCASDAKAYEKEVHNVWATHACVPTDPNPQEMVLANVTENFNMWKNDMVEQ 
HXBC2        -----------------------------------GARSEVVLVNVTENFNMWKNDMVEQ 
                                                   .*: * ***********:**** 
        V1/V2 Truncation 
93TH057      MQEDVISLWDQSLQPCVKLT----GG-----SVIKQACPKISFDPIPIHYCTPAGYVILK 
C1086        MHEDIISLWDESLKPCVKLT----GG-----SAITQACPKVSFDPIPLHYCAPAGFAILK 
HXBC2        MHEDIISLWDQSLKPCVKLTPLCVGAGSCNTSVITQACPKVSFEPIPIHYCAPAGFAILK 
             *:**:*****:**:******           *.*.*****:**:***:***:***:.*** 
 
93TH057      CNDKNFNGTGPCKNVSSVQCTHGIKPVVSTQLLLNGSLAEEEIIIRSENLTNNAKTIIVH 
C1086        CNNKTFNGTGPCRNVSTVQCTHGIKPVVSTQLLLNGSLAEEEIIIRSENLTNNAKTIIVH 
HXBC2        CNNKTFNGTGPCTNVSTVQCTHGIRPVVSTQLLLNGSLAEEEVVIRSVNFTDNAKTIIVQ 
             **:*.******* ***:*******:*****************::*** *:*:*******: 
      V3 Stabilization 
93TH057      LNKSVEINCTRPSNGGSGSGGDIRKAYCEINGTKWNKVLKQVTEKLKEHFN-NKTIIFQP 
C1086        LNESVNIVCTRPNNGGSGSGGNIRQAHCNINESKWNNTLQKVGEELAKHFP-SKTIKFEP 
HXBC2        LNTSVEINCTGA-------------GHCNISRAKWNNTLKQIASKLREQFGNNKTIIFKQ 
             ** **:* **               .:*:*. :***:.*::: .:* ::*  .*** *:  
       CD4-binding Loop 
93TH057      PSGGDLEITMHSFNCRGEFFYCNTTQLFNNTCIG---NETMK---GCNGTITLPCKIKQI 
C1086        SSGGDLEITTHSFNCRGEFFYCNTSDLFNGTYRNGTYNHTGR---SSNGTITLQCKIKQI 
HXBC2        SSGGDPEIVTHSFNCGGEFFYCNSTQLFNSTWFNSTWSTKGSNNTEGSDTITLPCRIKQI 
              **** **. ***** *******:::*** *      . .       . **** *:**** 
             β-sheet 
93TH057      INMWQGTGQAMYAPPIDGKINCVSNITGILLTRDGGANNTS--NETFRPGGGNIKDNWRS 
C1086        INMWQEVGRAIYAPPIEGEITCNSNITGLLLLRDGGQSNETNDTETFRPGGGDMRDNWRS 
HXBC2        INMWQKVGKAMYAPPISGQIRCSSNITGLLLTRDGGNSNN--ESEIFRPGGGDMRDNWRS 
             ***** .*:*:*****.*:* * *****:** **** .*    .* ******:::***** 
 
93TH057      ELYKYKVVQIE 
C1086        ELYKYKVVEIK 
HXBC2        ELYKYKVVKIE 
             ********:*: 
Figure 1 // Sequence alignment of new unliganded gp120 vs old ternary complex gp120. clade A/E93TH057 and 
clade C1086 contained in this work have truncations in V1/V2 loop and extensions in the V3 loop that allow 
crystalization without antibody fragment and CD4 that was necessary in the first gp120 crystal structure from clade 
B HXBc2 (PDB: 1GC1). * = fully conserved residue, : = conservation between groups of strongly similar properties, 
. = conservation between groups of weakly similar properties. Red = key residues for NBD-556 binding, Yellow = 







Figure 2 // Progression from NBD-556 to MAE-II-120. A. Crystal Structure of NBD-556 in gp120 clade 
C1086. Region I sits deep in the PHE43CD4 cavity, Region II provides a linker between the inner cavity to the 
cavity opening, Region III plugs the opening of the cavity. Figure based on PDB ID: 3TGS. B. 
Modifications of NBD-556 include additional halogen on the phenyl ring in Region I (yellow arrow) and a 
cyclobutane in Region III highlighted (red arrow). The two enanatiomers -R and -S in the racemic mixture 
of MAE-II-120 are also depicted with the chiral centers indicated by blue arrows. 
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Structural-activity relationships of MAE-II-120 
The crystal structure of NBD-556 in clade C1086 provided the foundation for our 
designs and optimization of NBD-derivatives. As seen in Figure 2A, the chloro-phenyl 
ring of region I sits deep in the PHE43CD4 cavity; region II links the inner cavity with the 
cavity opening; and region III has a tetramethylpiperdine ring that essentially plugs the 
opening of the PHE43CD4 cavity (Kwon et al, 2012).  To improve on the interactions of 
NBD-556, we added another halogen—a fluorine—at the meta position on the phenyl 
ring (yellow arrow in Figure 2B) to hopefully provide further van der Waals contacts 
deep in the cavity. The other modification to the NBD-556 paradigm is altering the 
tetramethylpiperdine ring (region III) with a cyclobutane to see if the new shape motif 
will provide novel interactions with the residues lining the opening of the PHE43CD4 
cavity.   
Our collaborators from the Amos Smith Lab at University of Pennsylvania 
synthesized a new NBD-derivative designated MAE-II-120 with the chloro-fluoro phenyl 
and cyclobutane modifications.  However, the synthesis resulted in a racemic mixture of 
two inseparable R- and S-enantiomers of MAE-II-120 due to its chiral center depicted in 
Figure 2B. It was unclear at this point if one, both or none of the MAE-II-120 

















3.7 ± 0.1 -7.4 ± 0.02 -24.5 ± 1.0 +17.5 ± 0.7 
MAE-II-120
 
0.63 ± 0.1 -8.5 ± 0.06 -18.8 ± 2.1 +10.3 ± 2.2 
Table 1 // Thermodynamics of racemic MAE-II-120 binding to monomeric gp120 YU2 strain. The 
values for the affinity (Kd and ΔG), ΔH and -TΔS were determined at 25 °C. Values for NBD-556 from 
(LaLonde et al, 2012).  !
Previous thermodynamic binding studies by our collaborative group indicated that 
the binding of NBD-556 to gp120 produces a favorable change in enthalpy (ΔH = -24.5) 
and a large unfavorable change in entropy (-TΔS = +17.1) indicating a molecular 
rigidifying and restructuring (LaLonde et al, 2012). Similar thermodynamic signatures 
(ΔH = -34.5 and -TΔS = +23.6) characterize sCD4-gp120 binding--alluding that NBD-
556 utilizes the same binding mechanism as CD4 (Schon et al, 2006).  For MAE-II-120, 
the thermodynamic data in this study shows a similar pattern of favorable enthalpy (ΔH = 
-18.8).  However, MAE-II-120 pays a preferably lower entropic penalty (-TΔS = +10.3) 
upon binding to gp120 indicting a more efficient binding event compared to its precursor 
NBD-556.  The Kd of 0.63 µM shows that MAE-II-120 not only induces a more efficient 
binding event but a tighter one as well in comparison to 3.7 µM Kd of NBD-556 (Table 
1).  
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The stoichiometry of MAE-II-120 titration curve (not shown) provides a clue into 
the racemic question of which enantiomer MAE-II-120-S or MAE-II-120-R binds to 
gp120.  The titration curve shows a single binding event with a stoichiometry of one 
indicating that both enantiomers of MAE-II-120 are binding with the similar 
thermodynamic characteristics and therefore with the same binding mechanism.  If one of 
the enantiomers binds while the other was a completely ineffective binder then the 
titration curve would have had a stoichiometry of two because twice as much of the 
racemic compound would have been needed to obtain the titration curve.  If both 
enantiomers bound but with different binding abilities then the titration curve would have 
shown a double binding event and no thermodynamic data would be available due to the 
complex nature of such titration curves.  In this case, MAE-II-120-S and MAE-II-120-R 
both bind with the exact same potency and thermodynamic properties indicating they 
both undergo the same binding mechanism to gp120.  To elucidate how two enantiomers 
with two different stereochemistries can utilize the same binding mechanism, we had to 
refer to the crystal structure.   
 
The Crystal Structure of MAE-II-120 bound to clade C1086 gp120   
The x-ray crystal structure of MAE-II-120 was determined from a fully-grown 
clade C1086 crystal soaked in an adapted mother liquor solution containing the compound 
of interest.  The structure of MAE-II-120 bound to gp120 diffracted to 2.7 Å in C2221 
space group. The crystal of MAE-II-120 can be divided down into discrete repeating unit 
cells containing two copies of gp120 each.   The structure was solve by molecular 
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replacement using the structure coordinates of unliganded clade C1086 gp120 (PDB 
ID:3TGR) (Kwon et al, 2012).  Once gp120 was refined by itself, an omit map (Fo-Fc) 
emerged indicating the possible binding orientation inside the PHE43CD4 pocket in one of 
the copies of gp120 for MAE-II-120.  At first, it was difficult to discern which 
enantiomer of MAE-II-120 could fit into the electron density.  However with the 
thermodynamic results suggesting that both enantiomers bind with the same affinity and 
binding mechanism, we were able to model both enantiomers to fit in the density and 
refined the structure with each enantiomer at 50% occupancy each.  Figure 3A and B 
shows the resulting 2Fo-Fc density encompassing both enantiomers.  The ligand density 
deep inside the PHE43CD4 cavity surrounding the chloro-fluoro phenyl ring and the 
oxalamide linker is well developed but deteriorates around the cyclohexane ring at the 
opening of the cavity. The electron density redevelops progressing toward the 








Figure 3 // Crystal structure of MAE-II-120 in gp120 clade C1086. A. Sideview of 2Fo-Fc electron 
density encompassing MAE-II-120-R and –S enantiomers.  B. Top view of 2Fo-Fc electron density 
encompassing MAE-II-120-R and –S enantiomers. C. Hydrogen bond interactions highlighted in dashed 
orange lines and van der Waals interactions highlighted in solid yellow lines. All ribbon and stick diagrams 
display gp120 C1086 in sky blue. In all figures, MAE-II-120-R is in dark grey and MAE-II-120-S in light 
grey. !
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Both MAE-II-120 enantiomers form hydrogen bonds between the oxalamide 
linker and residues GLY473gp120 and ASN425gp120 (Figure 3C). MAE-II-120-R 
oxalamide linker nitrogens form a 2.79 angstrom hydrogen bond with the main chain 
carbonyl oxygen of ASN425gp120 and a 3.23 angstrom hydrogen bond with the main chain 
carbonyl oxygen of GLY473gp120.  As for the other enantiomer, the MAE-II-120-S 
oxalamide linker nitrogens form a 2.90 angstrom hydrogen with the main chain carbonyl 
of ASN425gp120 and a 3.31 angstrom hydrogen bond with the main chain carbonyl of 
GLY473gp120.  
 
Figure 4 // Van der Waals contacts between MAE-II-120-R and –S and PHE43CD4 cavity, vestibule 
and opening. CHIEMRA was used to detect Van der Waals contacts (represented by black lines) defined 
by any two atoms radii within the distance of 0.0 to -0.4 Å apart.  
The well developed electron density of the double halogenated phenyl ring in 
region I and the oxalamide linker in region II can be explained by the multitude of van 
der Waals contacts combined with two hydrogen bond interactions with the interior of the 
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PHE43CD4 cavity.  As seen in Figure 4, double halogenated phenyl ring and oxalamide 
linker are well populated with van der Waals contacts; however as we progress toward 
the vestibule of the PHE43CD4 cavity, the piperdine ring is largely absent of van der 
Waals contacts. The relative abundance of van der Waals contacts along with the two 
hydrogen bonds of the oxalamide linker keep region I and II rigid deep in the PHE43CD4 
cavity.  On the other hand, the piperdine ring lacks any van der Waals contacts or 
hydrogen bonds to hold it rigid and therefore this may explain its lack of density. 
However, the new modification to region III in the form of a cyclobutane ring extended 
off the piperdine ring forms van der Waals contacts with the main chain atoms of residue 
GLY473gp120 and ASP474gp120 as well as the side chain of ASP474gp120.  These van der 
Waals contacts could be the possible explanation for the better developed density 
surrounding the cyclobutane section of MAE-II-120 suggesting that these contacts hold 
the cylobutane rigid and ordered adjacent to residues GLY473gp120 and ASP474gp120 
while the piperdine remains flexible and disordered due to its lack of contacts. The ability 
of both enantiomers of MAE-II-120 to make the same van der Waals contacts in the 
cavity opening can explain why MAE-II-120-R and –S bind with the same binding 
mechanism and produce the same thermodynamic characteristics.  
MAE-II-120-R and –S region III van der Waals interactions were a promising 
start to designing an NBD-derivative to have more interactions with the residues lining 
the PHE43CD4 cavity opening. With our next design, we sought to improve the design of 
region III to allow for possible hydrogen bond interactions, which are stronger than the 
weaker van der Waals dipole-dipole interactions. 
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Structural-activity relationship of DMJ-II-118b 
 
Figure 5 // DMJ-II-118b: a 50:50 racemic mix of DMJ-II118-R,R and DMJ-II-118-S,S. Important 
chemical groups labeled in blue text and chiral centers indicated by blue arrows. 
 
 Based on the possible contributions of the meta-fluoro addition on the chloro- 
phenyl ring, we kept the design motif for our next design.  We synthesized a newer NBD-
derivative preserving the chloro-fluoro phenyl and incorporating an amine group in 
region III to expand interactions around the cavity opening beyond van der Waals 
contacts.  The new compound DMJ-II-118b is designed with an indane in region III to 
provide more van der Waals contacts along with the methamine group that can provide a 
possible hydrogen bond with the residues lining the cavity opening.   
 Our collaborators at the Amos Smith Lab synthesized DMJ-II-118b as a 50:50 
racemic mix of enantiomers DMJ-II-118-R,R and DMJ-II-118-S,S due to two chiral 
centers highlight by blue arrows in Figure 5.  Without thermodynamic data and 
crystallographic structure, it was difficult to discern which enantiomer bound to gp120. 
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3.7 ± 0.1 -7.4 ± 0.02 -24.5 ± 1.0 +17.5 ± 0.7 
MAE-II-120
 
0.63 ± 0.1 -8.5 ± 0.06 -18.8 ± 2.1 +10.3 ± 2.2 
DMJ-II-118b
 
0.21 ± 0.05 -9.1 ± 0.09 -9.7 ± 0.5 +0.6 ± 0.04 
Table 2 // Thermodynamics of racemic DMJ-II-118b binding to monomeric gp120 YU2 strain. The 
values for the affinity (Kd and ΔG), ΔH and -TΔS were determined at 25 °C. The previous thermodynamic 
results for MAE-II-120 are listed again for comparison. Values for NBD-556 from (LaLonde et al, 2012). !
Compared to the Kd values of NBD-556 (3.7 µM) and MAE-II-120 (0.63 µM), 
the binding ability of DMJ-II-118b (0.21 µM) is a step in the right direction with a three-
fold increase in binding potency compared to MAE-II-120 (Table 2).  The entropic 
penalty (-TΔS) drops to almost zero; however the binding interaction is half as 
enthalpically favorable (ΔH) when compared to MAE-II-120—hence the similar free 
energy change (ΔG). The thermodynamic data suggests that the binding of DMJ-II-118b 
causes less restructuring/ordering of gp120 residues and less hydrogen bond formations 
through out the structure than its precursors.   
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The titration curve of DMJ-II-118b indicates that about 50% is binding 
competently.  It is plausible that the result from the titration can be explained by the one 
enantiomer that binds with an affinity of 0.21 µM, whereas the other enantiomer binds 
with an affinity that is so low that the binding event is not detectable. There is also a 
possibility that chemical degradation could have cause the inactive fraction. With the x-
ray crystal structure presented in the next section, we can at least determine which DMJ-














The Crystal Structure of DMJ-II-118b bound to clade C1086 gp120   
 
 
Figure 6 // Crystal structure of DMJ-II-118-S,S in gp120 clade C1086. A. Sideview of 2Fo-Fc electron 
density encompassing DMJ-II-118-S,S.  B. Top view of 2Fo-Fc electron density encompassing DMJ-II-
118-S,S. C. Hydrogen bond interactions highlighted in dashed orange lines.  All sections of figure display 
gp120 C1086 in sky blue and DMJ-II-118-S,S in light grey. !
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The x-ray crystal structure of DMJ-II-118 was determined and solved as 
previously described for MAE-II-120.  The structure diffracted to 2.8 Å in C2221 space 
group. The DMJ-II-118b/gp120 structure also has two copies of gp120 in the unit cell.   
The structure was solved by molecular replacement as previously described for MAE-II-
120.  Once gp120 was refined by itself, an omit map (Fo-Fc) emerged indicating the 
possible binding orientation inside the PHE43CD4 pocket in one of the copies of gp120 for 
DMJ-II-118b.  After trials of refinement testing both enantiomers, it appears that only 
DMJ-II-118-S,S can fit in the electron density apparent in the PHE43CD4 cavity. The 2Fo-
Fc electron density is developed throughout the compound and across hydrogen bond 
interactions (Figure 6A and B). 
The chloro-fluoro phenyl ring pharmacophore retained from MAE-II-120 design 
and as expected, it orients in the same position deep in the PHE43CD4 cavity. The fluorine 
makes van der Waals contacts with the conserved side chains of SER375gp120 and 
MET475gp120.  The oxalamide linker traverses similarly to MAE-II-120 from within 
PHE43CD4 cavity out to its opening.  As seen in Figure 6C, the nitrogens in the oxalamide 
linker form a 2.53 angstrom hydrogen bond with the main chain carbonyl of ASN425gp120 
and a 3.19 angstrom hydrogen bond with the main chain carbonyl of GLY473gp120.  Both 
oxalamide hydrogen bonds in DMJ-II-118 are more ideal and tighter in terms of 
angstrom distance in comparison to both enantiomers of MAE-II-120.  The more efficient 
oxalamide hydrogen bonds are possible contributors to the more potent Kd of DMJ-II-
118b.   
Along with the stronger versions of the two hydrogen bonds seen previously in 
MAE-II-120, the crystal structure of DMJ-II-118b also revealed a third hydrogen bond 
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with the main chain carbonyl of GLY472gp120 via a water molecule.  The conserved 
GLY472gp120 lies at the nexus between the outer domain and the inner domain region of 
gp120.  Although water mediated, the presence of the third hydrogen bond to a conserved 
residue gives a likely explanation to the improvement in Kd. 
 
Figure 7 // Van der Waals contacts of MAE-II-120-R/-S and DMJ-II-118-S,S. Crystal structure of 
MAE-II-120 enantiomers is depicted on the left and DMJ-II-118b on the right. Chimera was used to detect 
Van der Waals contacts (represented by black lines) defined by any two atoms radii within the distance of 
0.0 to -0.4 Å apart. 
Besides the new hydrogen bond interaction with GLY472gp120 on one side of the 
PHE43CD4 cavity opening, the new indane modification allows for new van der Waals 
contacts with residues lining the opposite side of the opening: GLY429gp120 and 
VAL430gp120 that was previously out of reach of MAE-II-120 and NBD-556 as compared 
in Figure 7.  
With the new van der Waals and hydrogen bond network interactions seen in 
DMJ-II-118-S,S, our group of collaborators sought to next design a new extension of the 
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indane in region III that would allow more possibilities of hydrogen bond interactions.  
The group replaced the amine with a guanidinium to provide more nitrogens to increase 
potential hydrogen bond interactions as well as to extend the reach.  Two compounds 
resulted from this effort: DMJ-II-228 possessing a guanidinium addition and DMJ-II-121 
possessing a methylguanidinium, which extended the reach even further.  DMJ-II-228 
structure was solved by our collaborators in the Peter Kwong Lab and DMJ-II-121 
structures were solved by us in the following section. 
 
Structural-activity relationship of DMJ-II-121-(racemic) 
 
Figure 8 // DMJ-121-(racemic): a 50:50 mix of DMJ-II-121-R,R and DMJ-II-121-S,S. Important 
chemical groups labeled in blue text and chiral centers indicated by blue arrows. 
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Our collaborators from the Amos Smith lab at University of Pennsylvania 
incorporated the new methylguanidinium design to the region III indane and preserved 
the chloro-fluoro phenyl, oxalamide linker and indane for DMJ-II-121.  The compound 
however was synthesized coupled with a counter formate ion as a 50:50 racemic mixture 
of DMJ-II-121-R,R and DMJ-II-121-S,S. The two enantiomers differ at the two chiral 
centers depicted in Figure 8. 
 
 Thermodynamic analysis of DMJ-II-121-(racemic) (performed by Arne Schon of 
John Hopkins University) 
 
Figure 9 // Calorimetric titration of gp120 with DMJ-II-121-(racemic) at 25°C. The double binding 
event shows the two enantiomers of DMJ-II-121 binding with different affinities.  Due to the complexity of 
the double binding event, thermodynamic data could not be calculated. 
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 The titration curve of gp120 with the racemic DMJ-II-121 shows two binding 
events representing one enantiomer binding with a higher affinity and one binding at a 
weaker but still detectable affinity; hence, thermodynamics of DMJ-II-121-(racemic) 
differs from the previous two NBD-derivatives in that MAE-II-120 has a pair of 
enantiomers that bind equally with similar thermodynamics and DMJ-II-118b has only 
one effective binder while the other enantiomer binds so poorly that it is undetectable 
(Figure 9).   Due to the complexity of double binding events, thermodynamic data from 
this isothermal calorimetry experiment could not be calculated.  The question of which 
enantiomer is the more potent binder will be answered in the next section which presents 
















Figure 10 // Crystal structure of DMJ-II-121-(racemic) in gp120 clade C1086.  The crystal structure 
indicates that the competent binder of DMJ-II-121 (racemic) is the –R,R enantiomer. A. Sideview of 2Fo-
Fc electron density encompassing DMJ-II-121-RR and associated formate ion.  B. Top view of 2Fo-Fc 
electron density encompassing DMJ-II-121-R,R and associated formate ion. Same as (A) but rotated 90° 
once around the Z- and X-axis. C. Hydrogen bond interactions of DMJ-II-121-R,R and the associated 
counter ion formate are highlighted in dashed orange lines. D. Hydrogen bond interactions of DMJ-II-121-
R,R and the associated water solvents are highlighted in dashed orange lines.  All sections of the Figure 
display gp120 C1086 in sky blue and DMJ-II-121-R,R in light grey. 
 
The x-ray crystal structure of DMJ-II-121 (racemic) was determined and solved 
as previously described for MAE-II-120 and DMJ-II-118b.  The structure diffracted to 
2.5 Å in C2221 space group.  Once gp120 was refined by itself, an omit map (Fo-Fc) 
emerged indicating the possible binding orientation inside the PHE43CD4 pocket in both 
copies of gp120. After trials of refinement testing both enantiomers, it appears that only 
DMJ-II-121-R,R can fit in the electron density apparent in the PHE43CD4 cavity. Figure 
10A and 10B presents the 2Fo-Fc electron density around DMJ-II-121-(racemic). The 
other copy has an equally developed 2Fo-Fc density around the ligand (not shown).  
However, the associated formate ion that was synthesized with DMJ-II-121-racemic 
could only be detected in one of the copies (Figure 10C) while the other copy has an 
extensive ionic hydrogen bond network in place of the formate (Figure 10D).  
 
Cavity interactions with Region I and II of DMJ-II-121-racemic 
The chloro-fluoro phenyl ring lies in the same orientation as the previous two 
NBD-derivatives and makes similar van der Waals contacts.  The oxalamide linker and 
its nitrogens lie in similar orientation making similar hydrogen bond interactions as the 
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previous DMJ-II-118b and MAE-II-120 structures. The oxalamide nitrogen closest to the 
opening on both copies also hydrogen bonds with ASP368gp120 via a water molecule. 
 
Vestibule interactions with Region III of DMJ-II-121-racemic 
The structural difference between DMJ-II-118 and DMJ-II-121 (racemic) lies in 
region III.  Both compounds have indane rings; however, DMJ-II-121 (racemic) has a 
methylguanidinium group providing more nitrogens for potential hydrogen bond 
interactions as well as a further reach outside the PHE43CD4 cavity compared to shorter 
methylamine group on DMJ-II-118b.  The methylguanidinium group does not orient 
itself toward GLY472gp120 to mimic the hydrogen interactions of DMJ-II-118b and its 
associated water molecule.  The methylguanidinium group actually orients in the opposite 
direction toward the bridging beta-sheet domain of gp120.  In this orientation, a nitrogen 
in the methylguanidinium makes a hydrogen bond with the main chain carbonyl of 
MET426gp120.   
Observations of interactions are similar in both copies up to this point.  In both 
copies, the methylguanidinium interacts further with several other residues lining the 
opening of the cavity but differ in the solvent ions it utilizes to accomplish these 





Vestibule interactions with Region III of DMJ-II-121-racemic through Formate Ion 
The copy of DMJ-II-121-racemic with the formate ion has a “boomerang” shaped 
electron density that indicates the proper size for a formic acid.  After refinement with the 
formate ion in place, we noticed that the solvent was within the proper distance (3.05 Å) 
and angle to the methylguanidinium nitrogen for hydrogen bond interaction with the 
ligand.  Furthermore, the formate ion is also in the proper hydrogen bond distance (2.53 
Å) and angle to the side chain of ASN425gp120; therefore linking DMJ-II-121-racemic to a 
residue lining the PHE43CD4 cavity opening. 
 
Vestibule interactions with Region III of DMJ-II-121-racemic through water 
network 
 
 When we tried to model in the formate ion in the second copy of DMJ-II-121-
racemic, the resulting shape of the 2Fo-Fc density as well as the emergence of negative 
Fo-Fc density signified that the formate ion was not likely present in this copy.  However, 
there were several separate electron densities extending off the methyl-guanidinium 
indicating the presence of water molecules and the ensuing modeled water solvents 
refined nicely into the structure.  With the solvent network in place, it appears that the 
methylguanidinium nitrogens on DMJ-II-121-racemic carry ionic interactions with 
GLY431gp120, GLY124gp120 and TRP122gp120 via a network of 4 water molecules.  All 
three mentioned residues are contained in the bridging sheet domain that is formed by 
two sets of beta-sheets β2/β3 and β20/β21 that come together when gp120 binds to CD4 
(Kwong et al, 1998; Chen et al, 2005).  
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Structural-activity relationship of DMJ-II-121-R,R 
 
Figure 11 // DMJ-II-121-RR single enantiomer with associated chloride ion. Important chemical groups 
labeled in blue text and chiral centers indicated by blue arrows. !
 After the successful determination of the DMJ-II-121 (racemic) crystal structure 
and the resulting isolation that the –R,R enantiomer is the active binder, our collaborators 
focused their efforts in synthesizing just the single –R,R enantiomer.  They were able to 
synthesize both the -R,R as well as the –S,S enantiomers separately.  Due to the new 
synthesis method, the single DMJ-II-121 enantiomers are now associated with a chloride 
counter ion instead of a formate ion previously seen with the racemic compound (Figure 
11).   
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3.7 ± 0.1 -7.4 ± 0.02 -24.5 ± 1.0 +17.5 ± 0.7 
MAE-II-120
 
0.63 ± 0.1 -8.5 ± 0.06 -18.8 ± 2.1 +10.3 ± 2.2 
DMJ-II-118b
 
0.21 ± 0.05 -9.1 ± 0.09 -9.7 ± 0.5 +0.6 ± 0.04 
DMJ-II-121-R,R 
 
0.11 ± 0.03 -9.50 ± 0.1 -17.9 ± 1.0 +8.4 ± 0.6 
DMJ-II-121-S,S 
 
6.2 ± 1.0 -7.1 ± 0.03 -19.7 ± 1.5 +12.6 ± 1.0 
Table 3 // Thermodynamics of racemic DMJ-II-121 binding to monomeric gp120 YU2 strain. The 
values for the affinity (Kd and ΔG), ΔH and -TΔS were determined at 25 °C. The previous thermodynamic 
results for MAE-II-120 and DMJ-II-118b are listed again for comparison. Values for NBD-556 from 
(LaLonde et al, 2012). 
 
Both enantiomers of DMJ-II-121 were separately tested in isothermal titration 
calorimetry experiments.  DMJ-II-121-S,S has a Kd of 6.2 µM which is almost twice as 
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ineffective at binding gp120 as the foundational NBD-556 (3.7 µM) (LaLonde et al, 
2012). However, its reciprocal enantiomer DMJ-II-121-R,R has a Kd of 0.11 µM making 
it our most potent compound designed to date at the time of this writing.  
The thermodynamic data shows that the less potent enantiomer DMJ-II-121-S,S 
has a favorable change in enthalpy (ΔH = -19.7) compensated by a large unfavorable 
change in entropy (-TΔS = +12.6); both parameters show similar values and hence a 
similar binding mechanism to MAE-II-120.  For DMJ-II-121-R,R, a favorable change in 
enthalpy (ΔH = -17.9) is coupled with a low entropic penalty (Table 3). As for the 
titration curves from the isothermal calorimetry experiments, the racemic DMJ-II-121 
curve shows a complex double binding event corresponding to enantiomer pairs binding 
at different affinities: DMJ-II-121-R,R at 0.11 µM and DMJ-II-121-S,S at 6.2 µM 
(Figure 12A). The titration curve for the single DMJ-II-121-R,R enantiomer shows a 
single binding event of only one compound binding at 0.11 µM (Figure 12B). Concluding 
that DMJ-II-121-R,R is the potent binder out of the two enantiomers, our efforts focused 
on solving a crystal structure of DMJ-II-121-R,R with gp120 to reconfirm the solution of 





Figure 12 // Comparison of Calorimetric titration of gp120 with DMJ-II-121-(racemic) and –R,R 
single enantiomer at 25°C. A. The titration curve of DMJ-II-121 (racemic) shows a complex double 
binding event indicating two enantiomers of DMJ-II-121 binding with different affinities. B. The titration 
curve of DMJ-II-121-R,R single enantiomer shows a single binding event from which appropriate 
thermodynamic calculations can be made. 
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The Crystal Structure of DMJ-II-121-R,R bound to clade A/E93TH057 gp120
 
Figure 13 // 2.5 Å X-ray crystal structure of DMJ-II-121-R,R in gp120 clade A/E93TH057. A. Side view 
of 2Fo-Fc electron density encompassing DMJ-II-121-R,R.  B. Top view of 2Fo-Fc electron density 
encompassing DMJ-II-121-R,R. C. Hydrogen bond interactions highlighted in dashed orange lines.  All 
sections of the Figure display gp120 in sky blue, DMJ-II-121-R,R in light grey. 
 
 The DMJ-II-121-R,R structured was solved bound to a different strain of gp120 
than the previous three structures.  The compound was co-crystallized with gp120 clade 
A/E93TH057 and diffracted to 2.5 Å in a P21 space group.   The crystal of DMJ-II-121-R,R 
can be divided down into discrete repeating unit cells containing two copies of gp120 
each. The structure was solved by molecular replacement using the structure coordinates 
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of unliganded clade A/E93TH057 gp120 (PDB ID:3TGT).  Once gp120 was refined by 
itself, an omit map (Fo-Fc) emerged indicating the possible binding orientation for DMJ-
II-121-R,R inside the PHE43CD4 pocket of both gp120 copies.  The 2Fo-Fc electron 
density map is well developed throughout the compound (Figure 13A and B).  
The previous racemic structure of DMJ-II-121-racemic/clade C1086 gp120 is 
essentially the same as the DMJ-II-121-R,R/clade A/E93TH057 which is not surprising 
since the only enantiomer capable of fitting in the electron density in the racemic 
structure was the DMJ-II-121-R,R enantiomer.  However, there are a couple differences 
between the two structures upon close comparison.  The elaborate ionic solvent network 
connecting DMJ-II-121-(racemic) to residues as far reaching as ones in the bridging sheet 
(β2) no longer exists. The explanation may lie in the observation that the single 
enantiomer DMJ-II-121 bound to clade A/E93TH057 gp120 has significantly less water 
molecules modeled into the structure (25 water molecules) compared to the racemic 
DMJ-II-121 bound in clade C1086, which had 259 water molecules. Secondly, the 
hydrogen bond interaction between the methylguanidinium and MET426gp120 main chain 
carbonyl seen in the previous racemic structure is now reinforced with a possible second 
hydrogen bond (Figure 13C).  More elaborations on differences and similarity are 
contained in the following Structural comparison of hydrogen bond and van der Waals 
interactions in NBD-derivatives section.  
 Not only did we find the single DMJ-II-121-R,R enantiomer in the PHE43CD4 
pocket but it also orients itself in a similar fashion as seen previously in the racemic 
DMJ-II-121 structure. The exchange of formate ion for a chloride ion in the new 
synthesis causes the new counter ion to no longer associate with the DMJ-II-121 in the 
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PHE43CD4 binding pocket.  Along with the thermodynamic data showing that the DMJ-
II-121-R,R is the more potent binder, the crystal structure of DMJ-II-121-R,R in clade 
A/E93TH057 gp120 verifies that we did in fact correctly solve the structure of the racemic 
mixture of DMJ-II-121 in clade C1086 gp120 with the correct enantiomer.  
Analysis of Region I interactions with PHE43CD4 cavity interior  
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Figure 14 // Comparison of van der Waals contact of Region I of NBD-Derivatives in PHE43CD4 
cavity. A. MAE-II-120. B. DMJ-II-118b. C. DMJ-II-121-racemic. D.  DMJ-II-121-R,R. All structures are 
oriented with the bridging sheet to the right and the inner and outer domain to the left. NBD-556 structure 
is from our collaborator’s previous work (Kwon et al, 2012). DMJ-II-118b, DMJ-II-121-racemic, DMJ-II-
121-R,R are from our work.  DMJ-II-121-R,R is bound in clade A/E93TH057 gp120 while the other three 
structures are bound in clade C1086 gp120.  Chimera was used to detect Van der Waals contacts (represented 
by black lines) defined by any two atoms radii within the distance of 0.0 to -0.4 Å apart. Only contacts for 
meta- and ortho- positions on the phenyl ring are displayed for simplicity.  !
! All four small molecular inhibitors presented in this dissertation are NBD-
derivative structures containing a double halogenated chloro-fluoro-phenyl ring in 
Region I.  The designs of the four small molecule compounds are based on NBD-556, 
which contains a single halogenated para-chloro phenyl ring.  Originally when we 
incorporated the second halogen to region I, we were not sure how the additional fluoride 
would affect the position of the phenyl ring.  Most likely due to the planar shape of the 
cavity, the new para-chloro meta-fluoro halogenated phenyl ring remains in parallel with 
the para-chloro phenyl ring of NBD-556 and in the same position deep in the PHE43CD4.  
Figure 14 compares the van der Waals contacts between the PHE43CD4 cavity and the 
meta- and ortho- atoms of the phenyl ring.  The original NBD-556 with a single 
halogenated phenyl ring makes a handful of contacts with the deep interior of the cavity 
(Kwon et al, 2012).  With the addition of a second halogen, the meta-fluoro always 
orients itself to the left in the general direction of the inner and outer domain of gp120 
and away from the bridging sheet on its right.  All four NBD-derivatives structures in this 
work showcase this orientation.  In this position, the double halogenated phenyl ring 
maintains van der Waals contacts with the side oriented toward the bridging sheet on its 
right and extends its reach to the left toward the inner and outer domain side--allowing it 
! 66!
to make contacts previously out of reach from the single halogenated phenyl ring of 
NBD-556.   




Figure 15 // Hydrophobicity surface diagrams of the PHE43CD4 cavity.  The most hydrophobic residues 
are highlighted in red and most hydrophilic in blue, with neutral residues in between the two ranges in 
white as assign by CHIMERA according to the Kyte-Doolittle hydrophobicity scale (Kyte & Doolittle, 
1982). MAE-II-120, DMJ-II-118b, DMJ-II-121-racemic are bound to clade C1086 gp120 and DMJ-II-121-
R,R is bound to clade A/E93TH057 gp120. Carbon atoms in compounds are colored light grey, nitrogens = 
blue, oxygen = red, fluorine = yellow, chlorine = green. 
 To answer the question why the newly added meta-fluorine orients itself toward 
the left in the Figure 14 and the direction of the inner and outer domain, we had to 
analyze the hydrophobic nature of the residues lining the deep interior of the PHE43CD4 
cavity using CHIMERA (Pettersen et al, 2004).  Figure 15 shows the PHE43CD4 cavity as 
neutral to hydrophobic in nature for both clade C1086 and clade A/E93TH057 gp120 
according to the Kyte-doolittle hydrophobicity scale (Kyte & Doolittle, 1982).  The 
vestibule opening of the PHE43CD4 cavity carries some hydrophilic residues highlighted 
in blue in both clades.  However, clade C1086 in the structures for MAE-II-120, DMJ-II-
118b and DMJ-II-121-(racemic) show a large hydrophobic region on the vestibule region 
closest to the bridging sheet (right relative to Figure 15). This hydrophobic patch is not 
present in clade A/E93TH057.   
 Deep inside the PHE43CD4 cavity, a hydrophobic patch of residues exist on the 
side closest to the inner and outer domain (left relative to Figure 15) in both clade C1086 
and clade A/E93TH057.  The presence of this hydrophobic patch provides an explanation on 
why the newly added meta-fluorine resides on this side of the cavity.  Due to the 
distribution of its electrons and therefore charge around the aromatic phenyl ring, the 
fluorine is basically non-polar and therefore ideal to have hydrophobic interactions with 
this side of the cavity.  There is a water channel on the opposite side of the interior cavity 
that is hydrophobic but this is slightly out of reach to have enough pull to orient the meta-
fluorine toward it.  
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Figure 16 // Ribbon and surface diagrams comparing van der Waals and hydrogen bond interactions 
between NBD-derivatives and the copies. Hydrogen bonds interactions are highlighted in yellow and van 
der Waals contacts in red. Hydrogen bonds are defined by a distance of 2.2 and 3.6 Å between donor and 
acceptor and with angles formed by donor, hydrogen, and acceptor between 90° and 180°. Van der Waals 
contacts are defined by any two atoms radii within the distance of 0.0 to -0.4 Å apart.  If a structure has two 
copies of compound bound to gp120 in the asymmetrical unit then both are shown.  Carbon atoms in 
compound are colored light grey, nitrogens = blue, oxygen = red, fluorine = yellow, chlorine = green and 
gp120 is depicted in sky blue. Water molecules involved in hydrogen bond network represented as red 
spheres. !
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In this body of work, we essentially have four structures of DMJ-II-121-R,R: the 
two copies in the asymmetric unit of DMJ-II-121-racemic/clade C1086 gp120 and the two 
in the single enantiomer DMJ-II-121/clade A/E93TH057 gp120.  For the most part, all four 
copies are essentially the same.  However, there are slight discrepancies between the 
copies as well as between the different clades of gp120.  As we zoom out to a broader 
comparison between the other two structures (MAE-II-120 and DMJ-II-118) as well as 
the original NBD-556, the major interactions reveal themselves as the most consistent 
between all the structures. Figure 16 gives an overall graphical representation of 
hydrogen bond and van der Waals interactions for all the copies of each structure while 
Table 4 quantifies each interaction. 
We utilized the program CHIMERA to identify both interactions in the fully 
refined PDBs of the crystal structures (Pettersen et al, 2004). Van der Waals interactions 
are defined by any two atomic radii within the distance of 0.0 to -0.4 Å.  Any atomic radii 
overlapping greater than 0.6 Å is considered a clash.  No clashes were found in any of the 
refined crystal structures. The hydrogen bond with a distance of 2.2 and 3.6 Å between 
donor and acceptor and with angles formed by donor, hydrogen, and acceptor between 
90° and 180° were detected using CHIMERA (McDonald & Thornton, 1994; Jeffrey, 
1997). The majority of the hydrogen bond distances fall between 2.2 and 3.2 Å between 
donor and acceptor.  The residues critical to previous NBD-derivative structures are 
highlighted in red in Table 5 (LaLonde et al, 2012). 
The two hydrogen bond interactions present in all the structures are the ionic 
interaction between the oxalamide linker nitrogens in region II of the compounds and the 
main chain carbonyl oxygen of conserved residues ASN425gp120 and GLY473gp120. This 
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is not surprising since the oxalamide linker is a preserved design motif in all compounds.  
A second hydrogen bond interaction between the methylguanidinium and the sidechain of 
ASN425gp120 can be seen in the DMJ-II-121-racemic copies facilitated by the solvent 
network. This is not present in the single enantiomer DMJ-II-121-R,R structure and 
maybe an artifact caused by the DMJ-II-121-racemic structure having 3-10 times more 
water molecules than our other structures.  The structure of NBD-556/clade C1086 solved 
in previous work by our collaborators showed evidence of the double oxalamide 
hydrogen bonds.  However, this is true only in one out of the two copies of NBD-
556/gp120 in the asymmetric unit.  The other copy is missing the GLY473gp120 hydrogen 
bond due to the oxalamide nitrogen being slightly off angle (Kwon et al, 2012).  Despite 
this, we are confident in the presence of the hydrogen bonds between the oxalamide 
linker and ASN425gp120 and GLY473gp120 considering it is present in all structures in this 
work. 
The hydrogen bond interaction that distinguishes DMJ-II-121 from the rest of the 
structures is between the carbonyl main chain oxygen of the conserved MET426gp120 
residue and the methylguanidinium group unique to compound and most likely the reason 
why DMJ-II-121 is our most potent and effective compound to date. The ionic interaction 
exists in all four copies of DMJ-II-121 in both racemic and single enantiomer structures.  
Both copies of the single enantiomer DMJ-II-121-R,R structure put the 
methylguanidinium close enough to form a second hydrogen bond with MET426.  
However since this second hydrogen bond cannot be seen in the racemic copies, we can 
only conclude that there is at least one hydrogen bond between methylguanidinium and 
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MET426gp120. Perhaps a higher resolution structure beyond the 2.5 Å resolution we 
achieved can settle the second MET426gp120 hydrogen bond question. 
Comparing the hydrogen bond and van der Waals interactions between the four 
copies of DMJ-II-121, all four make significant van der Waals contacts with the domains 
most proximal to the PHE43CD4 cavity opening: β20/21 and α5.  However, one of the 
copies of DMJ-II-121-racemic has an extensive water solvent network that extends ionic 
and van der Waals interactions to β2/3, which was out of reach from all previous 
compounds.  However, since this extensive reach of ionic interactions is not present in 
the other three copies, we are not confident that this is a real interaction until further 
high-resolution structures are obtained.  Another discrepancy in DMJ-II-121-racemic is a 
water mediate hydrogen bond to ASP368gp120 with the posterior oxalamide nitrogen.  
Although the ionic interaction is seen in both copies of DMJ-II-121-racemic, it is not 
seen in any other clade C1086 structures as well as the DMJ-II-121-R,R structure and is 
most likely just an artifact due to the relatively high number of water molecules and the 
lack of higher resolution. 
The β20/21 and α5 van der Waals contacts along with β15/16 interactions deep 
inside the cavity are consistent with the rest of the structures of DMJ-II-118, MAE-II-120 
and the original NBD-556.  DMJ-II-118b distinguishes itself from the rest of the 
structures by featuring a novel hydrogen bond mediated by an associated water molecule 
with GLY472gp120.  A hydrogen bond interaction has never been seen on the side of the 
cavity nearest to the inner domain in any other previous compound that our collaborators 
or we have worked on.  Even though this provides a third hydrogen bond interaction for 
DMJ-II-118b, it is an indirect hydrogen bond mediated by a water molecule.  The 
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improvement in potency from DMJ-II-118b to DMJ-II-121 is likely to lie in the fact that 
DMJ-II-121 achieves a third hydrogen bond directly instead of depending on water 
solvent for connection. 
Table 4 // Summary of all hydrogen bond interactions and van der Waals contacts between NBD-
derivative and binding site.  All side chains are conserved at least within the HIV-1 isolates with the 
exception of residues highlighted in blue. Residues in red are critical for previous NBD-derivatives. H = 
direct and h = indirect hydrogen bond through solvent network, * = direct and - = indirect van der Waals 
contact through solvent network. Van der Waals contacts defined by any two atoms radii within the 
distance of 0.0 to -0.4 Å apart.  Any overlap higher than 0.6 Å is considered a clash.  All interactions 
calculated with CHIMERA. 1Data for NBD-556 examined from (PDB ID:3TGS). 
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Figure 17 // Superpositions of all four crystal structures of NBD-derivatives and original NBD-556. 
A. Top view. B. 90° turn on X-axis and Y-Axis relative to A. C. 90° turn on Y-Axis relative to B.  
Superpositions performed by Matchmaker suite in CHIMERA using the crystal structure of unliganded 
clade C1086 gp120 (PDB ID:3TGR) as a reference (Pettersen et al, 2004).  MAE-II-120-R = yellow, MAE-
II-120-S = orange, DMJ-II-118b = green, DMJ-II-121 (racemic) = brown, DMJ-II-121-R,R = red, NBD-
556 = white (PDB ID:3TGS).  Ribbon diagram in the all figures represents clade C1086 gp120 unliganded 
crystal structure (PDB ID:3TGR).   
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   A superposition focusing on the NBD-derivatives along with the original NBD-
556 show the halogenated phenyl ring and oxalamide linker in all five compounds are 
oriented and align in the same fashion deep in the PHE43CD4 cavity (Figure 17).  The 
most significant structural differences lie in the region III and reveal different interactions 




Figure 18 // // Carbon backbone superposition of all four crystal structures of NBD-derivatives 
bound to gp120. Top trace compares clade C1086/ligand structures and the bottom is the same but with the 
addition of clade A/E93TH057/DMJ-II-121-R,R structure.  Superpositions performed by Matchmaker suite in 
CHIMERA using the crystal structure of unliganded clade C1086 gp120 (PDB ID:3TGR) as a reference 
(Pettersen et al, 2004).  MAE-II-120 = orange, DMJ-II-118b = green, DMJ-II-121 (racemic) = brown, 
DMJ-II-121-R,R = red.   
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Figure 18 analyzes the global conservation in structural similarity and quantified 
as root mean square deviation calculated during the superposition in Table 5. CHIMERA 
matchmaker program was used for the superposition (Pettersen et al, 2004). A neutral 
reference structure of unliganded clade C1086 gp120 (PDB ID:3TGR) was used as the 
reference structure for the superposition.  The top c-alpha backbone trace in Figure 18 
shows that all three clade C1086 structures are highly similiar.  DMJ-II-118b has the most 
conserved structural similarity to the unliganded clade C1086 structure with a RMSD of 
0.363 Å. Although all three structures are similiar, MAE-II-120/clade C1086 does have 
slight deviations in the N-terminus residues leading up to β1 in the inner domain region, 
at loop E and residues between β2 and β3 strands.  This particular region between β2 and 
β3 is where the truncation stem of the variable 1 and 2 loops were removed for 
crystalization purposes.!
DMJ-II-121-R,R single enantiomer was crystallized in a different gp120; although 
clade C1086 and clade A/E93TH057 are still structurally similar (Figure 18, bottom), the 
differences in amino acid sequence cause DMJ-II-121-R,R to have the highest RMSD out 
of the group but still structurally conserved overall at 0.684 Å (Table 5). The structural 
conservation across all NBD-derivatives bound to gp120 as well as across two different 
clades of gp120 could be attributed to the fact that the clade C1086 and A/E93TH057 gp120 
both crystallize in CD4-bound conformation and the binding of these NBD-compounds 
does not drastically change the conformation.    
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Test Structure # of Atom Pairs used 
in superposition 
RMSD (Å) 
DMJ-II-118b + clade C1086 328 0.363 
MAE-II-120 + clade C1086 332 0.456 
DMJ-II-121-racemic + clade C1086 328 0.378 
DMJ-II-121-R,R + clade A/E93TH057 323 0.684 
 
Table 5 // RMSD comparison NBD-derivative crystal structures. Superposition of all 4 NBD-
derivatives performed with Matchmaker in CHIMERA using the crystal structure of unliganded clade 
CC1086 gp120 (PDB ID:3TGR) as a reference (Pettersen et al, 2004).  # of Atom Pairs used in the 














Comparison of hydrogen interactions of guanidinium versus methylguanidinium in 
Region III 
          
Figure 19 // Comparison of hydrogen bond interactions between DMJ-II-228 and DMJ-II-121. A. 
DMJ-II-228 solved by our collaborators in the Peter Kwong Lab (PDB ID:4DKQ). B. DMJ-II-121 solved 
in this body of work. Hydrogen Bonds represented as dash lines. Water molecules involved in Hydrogen 
bond interactions represented as red spheres.  Kd values for DMJ-II-228 taken from (LaLonde et al, 2012).  
 To further support the strength of a direct hydrogen bond interaction versus one 
mediate by water solvents in terms of the binding ability of NBD-derivatives, we 
compared a companion structure to DMJ-II-121.  DMJ-II-228 solved by our collaborators 
at the Peter Kwong Lab is almost identical to DMJ-II-121; the difference is a carbon 
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distinguishing DMJ-II-121 with a methylguanidinium instead of a guanidinium in DMJ-
II-228.  Both are capable of interacting with MET426 through hydrogen bond 
interactions; the difference is that DMJ-II-228 relies on an ionic network of at least two 
water molecules to accomplish this while DMJ-II-121 is self-sufficient using the reach of 
its methylguanidinium to make a direct hydrogen bond with MET426.   This direct 
hydrogen bond is the possible key difference that grants DMJ-II-121 more than twice as 














Viral inhibition and activation analysis of the four NBD-derivatives (performed by 
Navid Madani of the Dana-Farber Cancer Institute) !
Compound Chemical Figure IC50 of HIV-1 on CD4+ cells (µM)a 
IC50 of A-MLV on 
CD4+ cells (µM)b 
Enhancement of 





>100 >100 1.0 
MAE-II-120 
 
42.3 ± 10.3 (9) 91.8 ± 3.9 (9) 2.27 ± 0.57 (7) 
DMJ-II-118b 
 













37.9 ± 22.7 (4) >100 0.11 ± 0.11 (2) 
 
Table 6 // Viral Assay analysis of NBD-derivatives. aCompound concentrations that inhibit 50% of viral 
infection were calculated using 10,000 RT units of wild-type YU2 HIV-1 expressing luciferase to infect 
Cf2TH-CD4/CCR5 cells with increasing concentration of the particular NBD-derivative. bControl 
experiment studying nonspecific inhibition using A-MLV envelope glycoprotein. cActivation of viral 
infection was determined by using recombinant YU2 HIV-1 to infect Cf2TH-CCR5+/CD4- cells in the 
presence of the particular NBD-derivatives. The IC50 and enhancement data are reported as a mean with 
standard deviation from the number of triplicate experiments represented in the parentheses. N/A signifies 
no experimental data available. NBD-556 data cited from (LaLonde et al, 2012). !
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 Viral enhancement studies allow for the validation of the ability of a small 
molecular entry inhibitor to block gp120 in a scenario with recombinant viruses 
expressing the HIV-1 Env protein gp120 as well as carrying a luciferase expression gene.  
In the experiment, the target canine cells express both CD4+/CCR5+.  The recombinant 
viruses use gp120 to bind to CD4 and CCR5 to invade the target canine cells. Once 
inside, the recombinant virus co-opts the genome of the target cell to produce luciferase 
and the luciferase activity is measured. Each compound is tested for its ability to block 
live recombinant viruses pseudotyped with CCR5-specific YU2 HIV-1 gp120 from 
entering Cf2TH CD4+/CCR5+ cells. As a control of specificity to the luciferase viruses 
with gp120, a recombinant virus carrying only the envelope glycoprotein from an 
unrelated retrovirus amphotropic murine leukemia virus (A-MLV) is also assayed in the 
same fashion.  The A-MLV Env protein uses neither CD4 nor CCR5 to invade the target 
cells but utilizes a Pit2 receptor that is naturally expressed on the canine cells.   
Out of the NBD-derivatives we designed, our thermodynamic studies show that 
DMJ-II-121-R,R is our most potent binder with a Kd value of 0.11 µM and the viral 
assay studies validates this assessment by showing it to be the most potent inhibitor of 
HIV-1 entry with an IC50 of 2.3 ± 0.7 µM.  Perhaps carried on the strength of having 
DMJ-II-121-R,R in its mixture, the second most effective inhibitor of HIV-entry is the 
racemic DMJ-II-121 with an IC50 of 10.3 ± 3.2 µM. DMJ-II-121-S,S and MAE-II-120 
have approximately similar inhibition ability even though DMJ-II-121-S,S is the poorest 
binder out of the group.  The similar favorable enthalpic and unfavorable entropic 
changes for both compounds may explain the similar inhibition ability despite the poor 
binding ability of DMJ-II-121-S,S (Table 6).  
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 All NBD-derivatives show specificity for inhibiting HIV-1 with the exception of 
DMJ-II-118b.  DMJ-II-118b is the worst inhibitor of the group and actually inhibits the 
control A-MLV better than it does HIV-1.  The explanation may lie in the racemic nature 
of the compound.  Both thermodynamic data and crystal structure reveal that only DMJ-
II-118-S,S binds to gp120 while suggesting its reciprocal enantiomer DMJ-II-118-R,R is 
basically so ineffective to the point of being undetectable. The dilution of the racemic 
mixture with the ineffective –R,R enantiomer could explain the poor HIV-1 inhibition 
ability.  While DMJ-II-118-R,R could be a poor binder to HIV-1, it may somehow 
possess the ability to inhibit the A-MLV.  This unsolicited behavior could explain the 
ability of the racemic mixture to inhibit the control better than HIV-1.  DMJ-II-118b also 
had solubility issues and when a compound comes out of solution, non-specific effects 
can arise. 
 The ability of NBD-derivatives to enhance HIV-1 ability to infect was studied in 
MAE-II-120.  CD4-/CCR5+ Cf2TH cells were exposed to YU2 HIV-1 in the presence of 
MAE-II-120.  Since CD4 is not present to induce gp120 into CCR5 binding 
conformation, any detected entry is a result induced by the small molecular inhibiter.  
The activation study suggests that the MAE-II-120 induces HIV-1 entry into CD4-
negative cells 2.27 ± 0.57 times as much as the foundational NBD-556.  The additions of 
the fluorine to the chloro-phenyl ring in region I and the cyclobutane to the piperdine ring 
in region III appear to induce gp120 into the CCR5 binding state more effectively then 
the NBD-556 pharmacophore.  A triplicate experiment for DMJ-II-121-racemic suggests 
that there is no activation. The results for the single enantiomer DMJ-II-121-R,R concurs 
with the non-activation results of the racemic counterpart.  The reciprocal enantiomer 
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DMJ-II-121-S,S has a slight but nominal activation level of 0.11 ± 0.11 relative to NBD-
556 enhancement. 
Binding Affinity versus Viral Inhibition: The Issue of Stoichiometry in HIV 
Infection 
 
 How do we explain the difference between the amount of NBD-derivative 
required to bind 50% of the population of gp120 (Kd) with the amount required to 
inhibiting 50% of HIV entry (IC50) in vitro?  For example, 0.11 ± 0.03 µM of our most 
potent binder DMJ-II-121-R,R is required to bind 50% of the gp120 population, while 
~21 times that amount is needed to inhibit 50% of HIV entry in vitro (2.3 ± 0.05 µM). 
The discrepancy between the IC50 versus Kd can be explained by the stoichiometry 
between the functional units of the Env protein and the co-receptors as well as the 
therapeutics that block them.  The question involves a complicated set of variables 
backed with data not enough to comfortably substantiate the handful of theories and 
models at this point in time.   
All our crystal structures consistently show that for each gp120 molecule only one 
NBD-derivative binds allowing a 1:1 stoichiometry between gp120 and NBD-derivative.  
This 1:1 ratio can be applied to all crystal structures of gp120 since up to this point all 
have been monomeric gp120 and not trimeric.  With this being said, an obvious 
difference between the ITC and the virology experiments is that the Kd binding assays 
test monomeric gp120 while the IC50 viral assays analyze gp120/gp41 in trimer form; The 
strain of HIV-1 was the same in both experiments: YU2.  Due to this, the only way the Kd 
and IC50 values would be similar is if the following conditions are true: 
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• There is only 1 functional trimer on the surface of HIV. 
• Only 1 functional trimer is needed for entry. 
• Blocking only 1 gp120/gp41 subunit in the trimer prevents fusion conformation. 
• The drug blocking the interaction is completely antagonistic.   
From our data, this is not the case. To fully explore the actual stoichiometry, one 
needs to first ask how many trimers are present on the surface of HIV? According to a 
cryoelectron microscopy study, there are 14 ± 7 trimers on the surface of a single HIV 
(Zhu et al, 2006).  However, many of these trimers are junk Env and nonfunctional which 
results from an inefficiency in the viral machinery for producing gp120 (Moore et al, 
2006).  
With this being said, how many functional Env trimers are needed for viral entry? 
A cryoelectron tomography study which combines 2D cryoelectron microscopy images to 
form a 3D rendering shows evidence of an entry claw composed of 5 to 7 rod-like 
structures forming a pore of ~300-400 Å in diameter.  However, the study could not 
confirm if these rod-like structures were the Env trimers (Sougrat et al, 2007). In 
opposition, two HIV entry studies provided data that suggests fusion requires only a 
single Env trimer (Yang et al, 2005; Zhu et al, 2006).  A mathematical model reanalyzing 
the data from these HIV entry studies refutes the claim of a single trimer and suggests 
that a virion carrying 9 trimers would need 5 to be functional for entry to occur (Klasse, 
2007).  Even if the field can confirm a threshold number for HIV entry, we still need to 
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ask if all three of the gp120/gp41 subunits that form the Env trimer need to bind to CD4 
in order for the trimer to assume the fusion conformation. 
 A mutation study engineered gp120/gp41 to be defective in select functions of 
CD4 binding, chemokine receptor binding and plunging of the gp41 hydrophobic head 
into the target cell membrane.  The study suggest that at least 2 out of 3 gp120/gp41 
subunits in the trimers need to be fully competent in all three functions in order for viral 
entry to occur.  Also inter-communication between subunits in the trimer is not apparent 
in the study—meaning one gp120 dysfunctional in chemokine binding cannot be 
compensated by one of the other two fully functional gp120 subunits in the trimer (Yang 
et al, 2006).    
 If two gp120/gp41 in a trimer need to be functional for trimer fusion 
conformation then only two CD4/gp120 antagonists are needed to prevent the trimer from 
fusing with the target membrane. If HIV only needs one functional trimer for fusion and 
there are 10 trimers on the surface of the HIV particles then in order to block HIV entry, 
all 10 trimers need to be blocked on the virus; In order to block each trimer, at least 2 
gp120/gp41 subunits on each trimer need to be inhibited. This stoichiometry in this 
model suggest that the IC50 should be 20 times the Kd which correlates roughly to the 
discrepancy between the IC50 and Kd of our most potent binder DMJ-II-121-R,R.  
However, the data in the field of HIV stoichiometry is not to the point where any of these 
conclusions can be made.   
 Despite the stoichiometry conundrum, the viral experiments show that DMJ-II-
121-R,R is our most potent viral inhibitor confirming the results of the ITC experiments.  
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Not only is DMJ-II-121-R,R our most potent inhibitor designed to date but it also shows 
no signs of activating gp120 into coreceptor binding state which is ideal considering the 
small molecule interacts with the same binding site as the natural ligand; therefore 
categorizing DMJ-II-121-R,R as an antagonist and not an agonist. 
 
Conclusion 
 The four crystal structures in this section have provided valuable structural 
guidance that has allowed us to identify the proper enantiomers issues raised by racemic 
synthesis, to explain peculiar binding characteristics observed in isothermal calorimetry 
experiments and improved the Kd of NBD-compounds more than 30 fold from 3.7 µM to 
0.11 µM.  Although our most potent compound DMJ-II-121 is still not in the ideal 
subnanomolar range, the optimization of these NBD-derivatives represents a significant 
step in the right direction toward an effective small molecular entry inhibiter targeting 































 Conventional techniques for screening lead compounds involve a biochemical assay that 
tests a library of assorted compounds with the target protein in solution.  Both NBD-556 and 
BMS-806--mentioned in Chapter I--were discovered using this particular technique (Lin et al, 
2003; Zhao et al, 2005).  In general, compounds in biochemical assay screens generally need to 
be in the micromolar range in order to be indentified.  Any compound can be broken down into 
smaller fragments—each with their own chemical reactive groups.  Due to the possibility of 
highly localized concentrations of candidate fragments in protein crystals, the x-ray 
crystallographic fragment based screenings allow for identifications of very weak binding 
compounds on the order of 1 mM (Gill et al, 2005).   Since the initial identified fragments carry a 
mass in the 120-250 dalton range, the low molecular size allows sufficient room for potency 
optimization by adding additional chemical motifs to the base fragment (Gill et al, 2005).  Since 
the x-ray crystallographic screening itself provides an image of the binding position of the 
fragment, sites of chemical elaboration can be easily pinpointed and utilize to guide synthesis.  
There are two essential requirements for a fragment based lead discovery system using x-ray 
crystallography: a library of appropriately organized screening fragments and a soakable 
unliganded crystal system that can accept multiple fragments at a time.   
Zenobia Fragment Library 
The Zenobia fragment library offers 352 compounds organized into 44 separate shape 
diverse groups of 8 fragments each. When a x-ray crystal structure reveals a positive hit in the 
form of a electron density in the known binding pocket, one can easily identify which fragment 
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bound by matching it to one of the diverse shapes organized in the group of 8 fragments. Table 1 
lists the mean properties of the fragments included in the Zenobia Library. 
Molecular Weight (Daltons) 154.2 
# of H-Bond donors 1.4 
# of H-Bond acceptors 2.6 
Solubility (ClogP) 1.6 
Polar Surface Area (Å2) 52.1 
!
Table 1 // Mean characteristics of fragments in Zenobia Library 
  
The overall fragment characteristics fall nicely under the “Rule of Three” which 
highlights the most common attributes of fragments that lead to positive hits in screens 
(Congreve et al, 2003): 
Rule of three for fragment attributes 
• Molecular weight < 300 daltons 
• # of H-bond donors ≤ 3 
• # of H-bond acceptors ≤ 3 
• ClogP ≤ 3 
The molecular weight of a fragment needs to be under 300 daltons in order to leave room 
for elaboration and optimization to a fully realized small molecule drug compound.  Once a 
fragment is identified in the binding pocket, it will be used as a starting point to attached other 
chemical groups to take advantage of hydrogen bond and van der Waalss contacts available in 
the regions of the binding pocket that have not yet been exploited.  Since attaching more 
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chemical groups to the fragment will increase the mass of the final compound, the fragment 
needs to be under a certain molecular weight to allow the final compound to still fall under 500 
daltons as dictated by the “rule of five” which applies to full size drug compounds (Lipinski et al, 
2001).  The hydrogen bond-donor and –acceptor number and ClogP of the rule of three for 
fragments also need to fall under these requirements for the same reason. 
Rule of five for drug compounds 
• Molecular weight < 500 daltons 
• # of H-bond donors ≤ 5 
• # of H-bond acceptors ≤ 10 
• ClogP ≤ 5 
The number of hydrogen bond donors is defined as sum of NHs and OHs while the 
number of acceptors is the sum of Os and Ns in a fragment or drug compound.  Designing a 
fragment or compound with more hydrogen bond donors and acceptors increases the likelihood 
for potential ionic interaction with the target-binding site.  However this comes at a cost because 
the more hydrogen bond donors and acceptors a fragment or compound has, the less permeable it 
is across the bilipid barrier of the intestinal epithelium--affecting its ability to be an orally 
absorbed drug.  The ClogP attribute takes this one step further and calculates the bilipid 
permeability of the fragment or compound as a whole. 
The ClogP is a computer algorithm that calculates the partition coefficient a fragment or 
compound. The partition coefficient (logP) is the logarithm of the ratio of compound 
concentrations in a mixture of two immiscible phases at equilibrium: one phase is a polar solvent 
such as water and the other is nonpolar, normally octanol.  The aqueous phase is pH adjusted so 
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the solute under investigation is not ionized and the partition coefficient is calculated with 
equation 1 (Leo A, 1971).   
                              [solute]octanol 
log Poctanol/water = log ___________________________ 
                              [solute]un-ionized water 
 
Equation 1 // The formula for calculating the partition coefficient. 
! In essence, the partition coefficient measures the hydrophobicity of a 
fragment/compound.  An ideal drug needs to be both in a “goldilocks” range of hydrophobicity: 
hydrophobic enough to partition into the intestinal epithelium lipid bilayer but hydrophilic 
enough to pass through to the other side (Kubinyi, 1979).  The threshold for this to occur under 
the rule of five is a ClogP ≤ 5. 
 
Unliganded clade C1086 gp120 soakable crystal system 
With the advent of the unliganded clade C1086 gp120 soakable crystal system by the Peter 
Kwong Lab, we had a crystal system with an already identified binding pocket. The gp120 is 
also already crystallized in CD4 bond formation for facilitated soaking without danger of 
induced conformational changes that may result in crystal cracks.  We were able to grow a 
stockpile of unliganded clade C1086 gp120 crystals ahead of time and transport crystals out to 
X4C beamline at Brookhaven National Laboratory.  We would perform 1-hour crystal soaks in 
real time for groups of 4 shape-diverse fragments at a time for a final concentration of 1.25-2.5 
mM for each fragment involved. We were able to utilize this system to undergo crystal 
screenings of a fragment library acquired from Zenobia to explore possible leads for future 
designs separate but in parallel to our designs based on NBD-derivatives in the previous chapter. 
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Results and Discussion 
Overview of Zenobia Fragment Library using clade C1086 gp120 crystal system 
 Out of the 352 fragments available in the Zenobia Library, we were able to soak and 
examine the crystal structures of 172 fragments at this point in time.  Even though we have only 
examined half the library, we already obtained two positive hits that may lead to future design 
motifs.  
We identified each fragment by using the structure of unliganded clade C1086 gp120 (PDB 
ID:3TGR) as a search model for molecular replacement and one round of refinement in PHENIX 
(Adams et al, 2010; Kwon et al, 2012).  We would examine the PHE43CD4 cavity in each 
structure, searching for a Fo-Fc electron density that was big enough in size and correct shape to 
incorporate a model of any of the eight fragments in the soaking group.  If a fragment does fit 
into the Fo-Fc electron density then another refinement is performed with the fragment in the 
density.  We examined the resulting 2Fo-Fc eletron density shape to evaluate how well the 
density enveloped the fragment as well as any negative density from the Fo-Fc map.  If the Fo-Fc 
map shows no sign of rejection and the shape of the 2Fo-Fc electron density envelops the 
fragment model in a convincing manner then we would categorize the fragment as a positive hit 
for further study and elaboration.  For the two positive hits so far, it was fairly easy to determine 
which of the eight fragments bound due to the easily deducible differences in shape. The 






The following lists each crystal soaking experiment we performed and the chemical figures 
of the eight fragments in each group.  
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Figure 1 // Fragment groups soaked into clade C1086 unliganded gp120 crystals. Each group represents 
a single crystal soaking experiment showing the eight fragments soaked simultaneously in an unliganded 
clade C1086 gp120 crystal.  The two positive hits from the screen are highlighted in yellow. !
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 Screening half the fragments in the Zenobia library produced two positive hits 
highlighted in yellow in Figure 1.  A benzimidazole was isolated from a 2.6 Å crystal 
structure of Plate 1 group 1 soaking experiment.  Examining the shapes of the 5-
bromouracil, 4-bromobenzamide, isonipecotamide, 2-amino-6-bromopurine, 1-
aminoisoquinoline, 4-aminopyrimidine, 6-hydroxypicolinic acid and benzimidazole 
included in the soaking group, the shape and size of the electron density only allowed for 
benzimidazole to fit.  Once benzimidazole was identified, we had the opportunity to soak 
in benzimidazole by itself at 10 mM in a new unliganded clade C1086 gp120 crystal and 
solved the structure in the same manner to obtain a 2.7 Å structure seen in Figure 2A.  
The second hit was a 3-hydroxyphenylacetic acid isolated from a 2.3 Å crystal structure 
of Plate 2 group 5 soaking experiment. It was fairly easy to identify the shape of 3-
hydroxyphenylacetic acid from the others in the soaking group: 3-hydroxypyridine, 2-
(trifluromethyl)benzimidazole, 2-chloro-4-methylquinoline, 3-fluro-p-anisidine, 2-
methylresorcinol, 8-nitroquinoline and 3,4-dihydroxybenzoic acid (Figure 2B).  
 
Figure 2 // 2Fo-Fc electron density of  two positive hits from x-ray crystal screening of the Zenobia 
Library. A. Benzimidazole. B. 3-hydroxyphenylacetic acid. The ribbon diagram represents clade C1086 
gp120.  2Fo-Fc was set at 0.9σ. Fragments are represented as sticks with carbon atoms colored light grey, 




hydroxyphenylacetic acid sits at the cavity opening!(Figure!3A)!and!benzimidazole!resides!deep!in!the!interior!(Figure!3B). We superimposed both fragments over the 
structure of DMJ-II-121-racemic since all three are bound to the same clade C1086 gp120.  
In Figure 3C and D, benzimidazole can be seen overlapping!with!the!halogenated!phenyl!ring!of!Region!I!on!DMJRIIR121Rraecmic.!!3-hydroxyphenylacetic acid!on!the!other!hand!overlaps with both the posterior end of the oxalamide linker in Region II and 











Figure 3 // Superposition of the two positive fragment hits with DMJ-II-121-racemic/clade C1086 
gp120. A. 3-hydroxyphenylacetic acid at the PHE43CD4 opening. B. Benzimidazole deep in the interior of 
the PHE43CD4 cavity with associated water as red spheres. C. Superposition with ribbon diagram of gp120. 
D. Superposition with surface of the PHE43CD4 cavity. Benzimidazole carbons are colored yellow. 3-
hydroxyphenylacetic acid carbons are colored in sky blue.  DMJ-II-121-racemic is colored in light grey. 
Ribbon and surface diagrams are the clade C1086 gp120 from 3-hydroxyphenylacetic acid x-ray structure. 
Oxygen atoms are colored red and nitrogen = blue. 
 
 
Hydrogen Bond Interactions of Fragment Hits 
We used CHIMERA to detect hydrogen bonds using the same criteria as 
mentioned in the previous chapter.  The benzimidazole has a similar ionic interaction 
with gp120 as seen with DMJ-II-118b.  Both fragment and NBD-derivative have 
hydrogen bond interactions with GLY473 via a water solvent.  As for 3-
hydroxyphenylacetic acid, it not only makes a novel ionic interaction with GLU370 but 
also a direct bond signifying a more effective interaction with the PHE43CD4 binding 
pocket.  GLU370 forms the “upper roof” of the immediate interior from the vestibule. A 
hydrogen bond interaction with this residue has not been detected before in any previous 
NBD-derivatives (Figure 4). 
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Figure 4 // Hydrogen bond interactions of two positive fragment hits.  Hydrogen bonds are represented 
by dashed orange lines and associated water solvents as red spheres. Fragment carbons are colored light 
grey.  clade C1086 gp120 carbons are sky blue.  Oxygen atoms are red, nitrogen atoms = blue, sulfur yellow. ! !
Table 2 quantifies the hydrogen bond interactions and van der Waals contacts for 
both fragments.  We also used CHIMERA to detect all atoms of the fragments that are in 
appropriate range for van der Waals interaction with the PHE43CD4 cavity surface using 
the same criteria as mentioned in the previous chapter.  Since the fragments possess 
fewer hydrogen donors and acceptors than fully realized compounds, we were not 
expecting as many hydrogen bonds interactions in comparison.  However, we are happy 
to report that each of the two fragments is able to take advantage of one of their hydrogen 






Table 2 // Summary of all hydrogen bond interactions and van der Waals contacts between fragment 
screen hits and PHE43CD$ binding site.  All sidechains are conserved at least within the HIV-1 isolates. 
Residues in red are critical for previous NBD-derivatives. H = direct hydrogen bond, h = indirect hydrogen 
bond through solvent network, * = direct van der Waals contact, - = indirect van der Waals contact through 
solvent network. Van der Waals contacts defined by any two atom radii within the distance of 0.0 to -0.4 Å 
apart.  Any overlap higher than 0.6 Å is considered a clash.  All interactions are calculated with chimera.  !
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 As for van der Waals forces, Figure 5 shows that 3-hydroxyphenylacetic acid 
mainly interacts with the vestibule opening of the PHE43CD4 and has no interaction with 
the interior of the pocket.  While benzimidazole--bound deep in the pocket--has 
interactions mostly deep with in the pocket, it also has some indirect van der Waals and 
hydrogen interactions with the opening of the cavity thanks to an ionicly associated water 









Figure 5 // Ribbon and surface diagrams comparing van der Waals and hydrogen bond interactions 
between NBD-derivatives and the copies. Hydrogen bonds interactions are highlighted in yellow and van 
der Waals contacts in red. Carbon atoms in compounds are colored light grey, nitrogens = blue, oxygen = 
red and clade C1086 gp120 are depicted in sky blue. Water molecules involved in hydrogen bond network 





 Even though we were only able to complete half of the Zenobia fragment library 
screen, we already obtained two positive and promising hits.  The results so far fall 
within the lower range of the 1-4% success rate promised by the Zenobia fragment 
library.  Benzimidazole and 3-hydroxyphenylacetic acid show capable hydrogen bond 
and van der Waals interactions even for their limited chemical complexity and fewer 
number of hydrogen bond donors/acceptors relative to full size compounds.  The present 
interactions observed in this chapter can be incorporated into future chemical 
elaborations using the data as a stepping stone to provide alternative paradigms to 
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HEK 293 GnTi- cells were chosen as a mammalian expression system due to their lack of 
N-acetylglucosaminyltransferase I (GnTI) activity allowing the proteins expressed to lack 
complex N-gylcosylation.  The GnTI- cells were adapted from adherent culture to free 
suspension in ordered to double and even triple the protein expression compared to adherent 
culture expression.  The cells were adapted to free suspension by a three day incubation in 
FreeStyle293 expression medium with 5% FBS and 1% PenStrep (Invitrogen).  After 3 days, the 
cells were grown in the same FreeStyle293 expression medium but with 2% ultralow IgG FBS 
and 1 x L-glutamine (Invitrogen). After at least 2 passages in suspension medium, the GnTI- 
cells were harvested at a concentration of 1.2 million cells per ml in 1 liter of FreeStyleTM 293 
expression medium.   
Plasmids for gp120 clade C1086 and clade A/E93TH057 constructs were transferred to our lab 
from our collaborators at the Peter Kwong group (NIH) (Kwon et al, 2012).  The minimum cell 
viability for transient transfection is 96% and this was determined using tryphan blue exclusion 
with a hemacytometer.   For the DNA/293 fectin mixture, 1 ml of 293Fectin was diluted into 25 
mls of Opti-Mem transfection medium (Invitrogen) and incubated at room temperature for 5 
minutes. Meanwhile, 500 µg of gp120 plasmid DNA was also diluted into 25 mls of Opti-Mem 
and sterilized through a 0.2 µm filter.  The diluted DNA/Opti-Mem was added to the incubating 
293Fectin/Opti-Mem solution and incubated for another 20 minutes at room temperature.  The 
50 ml DNA/293Fectin mixture was gently mixed into the viable GnTI- cells contained in a 2L 
shake flask and incubated at RT for 10 mins.  After RT incubation, the transfected cells were 
shaken at 125 rpm at 37°C in 8% CO2 for 4hrs.  After 4hrs in the shaker incubator, transfection 
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medium was decanted and fresh suspension medium of FreeStyle293 expression medium with 
2% ultralow IgG FBS and 1x L-glutamine was added to a level of 0.9 L.  The transfected cells 
were placed back in the shaker incubator for 5 days.  To enhance expression, add 3% Cell Boost 
(HyClone) and 2 mM butyrate (Sigma) were added to transfected cells to enhance protein 
expression and incubated at 37°C, 8% CO2, 125 rpm for 5 days.  The supernatant containing the 
secreted gp120 is harvested and centrifuged at 6700 rpm in a Sorvell SLC-4000.  The 
supernatant is decanted through a 500 ml bottle top filter (Corning) into a sterilize flask with 1 
tablet of Complete EDTA-free protease inhibitor and 0.02% NaN3.   
Purification of gp120 
100 mg of 17b antibody was conjugated to 20 mls of Protein A resin to make the 17b 
column to elute the gp120. 17b antibody has the ability to bind to the CCR5 binding site of 
gp120.  The supernatant was drip through the 17b column at 1 drop/sec then the column was 
washed with 100 ml or 5 column volumes of 1x PBS.  The gp120 bound to the conjugated 17b 
resin was eluted with IgG elution buffer (Pierce). To prevent the acidic pH of the IgG elution 
buffer from denaturing gp120, the mixture was neutralized back to pH 7 immediately with Tris 
pH 8. The 17b affinity column was restored with 2 column volumes of IgG elution buffer and 2 
column volumes of PBS.   
Deglycosylation 
The eluted gp120 was then concentrated below 4 mls for deglycosylation reaction at a 
concentration of 2-3 mgs per ml using a 10 kda centrifugal concentrator.  After taking a small 
aliquot for a 0 hr time point, 7-8 mg of glycosylated gp120 was added to a 4 ml deglycosylation 
reaction (50 mM NaAcetate pH 6, 5 mM EDTA, 500 mM NaCl, 500,000 U Endo H, 1 µg/µl 
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Leupeptin, 1 µg/µl Aprotonin).  The gp120 was deglycosylated overnight in a 37°C water bath.  
After checking for complete deglycosylation with a protein gel, the gp120 was dialyzed in a 
Slide-A-Lyzer dialysis cassette (Thermo) with Conclavin A buffer (40 mM Tris HCl pH 7.4, 1 M 
NaCl, 2 mM MnCl2, 2 mM CaCl2) in preparation for Con A purification.  After the first 30 mins 
of dialysis, the cassette was taken out and rinsed and submerged in 500 ml of fresh Con A buffer.  
The Con A column was made with 1 ml of Con A resin in a 10 ml plastic column at RT. The 
resin was washed with 20 ml ultra pure water and then 20 ml of Con A buffer. Another 20 ml of 
Con A buffer was added to fully equilibrate the Con A resin.  The dialyzed deglycosylated gp120 
was passed through the Con A column at a rate of 1 drop/sec. The flow through was collected.  
The Con A column was washed 3 more times with 1 ml Con A buffer—each time the wash was 
collected in separate tubes.  The fully deglycosylated gp120 passed through the Con A column in 
the elution and washes while any glycosylated gp120 remained bound to the Con A column.  A 
Superdex 200 column (GE Healthcare) was used for the final purification step. The purified 
gp120 was concentrated with a centricon 10 in 2.5 mM Tris-HCl pH 7.5, 350 mM NaCl, O.02% 
NaN3 to 10.5 mg/ml for clade C1086 and 15.6 mg/ml for clade A/E93TH057.  
Crystallization and fragment/compound soaking 
For crystal structures using clade C1086 gp120, the reservoir solution was 18-20% (w/v) 
PEG 1500, 0.1 M CaCl2, 0.1 M imidazole pH 6.5. 0.5 µl of the reservoir solution was mixed with 
0.5 µl of purified clade C1086 gp120. The proteins crystals grew overnight at 20°C using the 
hanging drop vapor diffusion method.  For each experiment, the compound/fragment of interest 
is dissolved in a 100% DMSO.  A single crystal was picked from the mother liquor and soaked 
in 5 µl of a stabilization buffer that contained the 26% PEG 1500 (w/v), 0.1 M CaCl2, 0.1 M 
imidazole pH 6.5, 2.5 mM Tris-HCl pH 7.5, 350 mM NaCl, O.02% NaN3, 5% (v/v) DMSO and 
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200 µM of the compound or 1.25 - 2.5 mM of the fragment of interest.  The clade C1086 gp120 
crystals were soaked for 30-60 min in the stabilization buffer.  And then transferred for 5 
seconds in cryo-protectant, which is the stabilization buffer but with 30% ethylene glycol. The 
crystal was then flash frozen in liquid nitrogen.  Diffraction data for clade C1086 crystals were 
collected at X4C beamline at Brookhaven National Laboratory. 
Co-crystallization 
For crystal structures using clade A/E93TH057, the reservoir solution was 11-12% PEG 
8000 (w/v), 5% isopropanol, 0.1 M HEPES pH 7.5.  The compound/fragment of interest was 
dissolved in 100% DMSO.  0.5 µl of the reservoir solution was mixed with 0.5 µl of purified 
clade A/E93TH057.  The proteins grew at 20°C using the hanging drop vapor diffusion method.  
Diffraction data for co-crystals of clade A/E93TH057 were collected on 24-ID-E beamline at 
Argonne National Laboratory.   
Crystallographic Data Processing and Refinement 
 HKL2000 program package, XDS and RAPD were used for data processing and 
reduction (Kabsch, 2010; Otwinowski, 1997).  Crystal structures were solved by molecular 
replacement module in PHENIX using unliganded clade A/E93TH057 gp120 (PDB ID:3TGT) and 
clade C1086 gp120 (PDB ID:3TGR) as search models (Adams et al, 2010; Kwon et al, 2012). 
Structure coordinates and library restraints of novel small molecule compounds (MAE-II-120, 
DMJ-II-118-R,R, DMJ-II-118-S,S, DMJ-II-121-R,R, DMJ-II-121-S,S) were generated with the 
Sketcher module in HKL2000 (Otwinowski, 1997).  Library restraints were also generated and 
edited with PHENIX: eLBOW and REEL modules (Adams et al, 2010).  Between refinements 












gp120 clade clade C1086 clade C1086 clade C1086 clade A/E93TH057 
  Data Collection 
Space Group C2221 C2221 C2221 P21 
a, b, c (Å) 67.56, 128.3, 193.2 67.64, 128.2, 193.0 67.45, 127.7, 192.9 65.32, 68.78, 94.44 
α, β, γ (deg) 90.00, 90.00, 90.00 90.00, 90.00, 90.00 90.00, 90.00, 90.00 90.00, 90.89, 90.00 
Resolution (Å) 2.54 – 48.3 2.79 – 48.2 2.50 – 38.6 (2.56-
2.50) 
2.21 –  94.4 (2.32 – 
2.21) 
RMerge 0.14 (0.82) 0.14 (0.55) 0.082 (0.83) 0.120 (0.027) 
Completeness (%) 99.9 (100) 99.8 (99.7) 99.9 (100) 94.9 (74.5) 
I/σ 12.94 (1.42) 14.4 (1.6) 22.7 (3.8) 9.0 (2.6) 
Redundancy 6.34 (5.2) 7.1 (6.6) 8.2 (8.3) 1.84 (1.43) 
# of unique 
reflections 
23474 21041 29249 (2108) 40186 (4499) 
 Refinement  
Resolution (Å) 2.70 - 48.3 2.80 – 33.8 2.50 – 29.8 2.50 – 33.63 
Rwork/Rfree (%) 22.24/26.84 22.60/25.96 25.38/27.47 19.54/26.28 
# of Atoms     
Ligand 219 240 241 310 
Water 93 22 259 25 
Protein 5496 5262 5270 5341 
B-Factors     
Ligand 42.34 78.9 50.7 65.4 
Water 31.48 49.9 29.2 47.7 
Protein 45.44 82.4 40.8 59.4 
RMSD     
Bond length (Å) 0.011 0.002 0.025 0.020 








gp120 clade clade C1086 clade C1086 
 Data Collection   
Space Group C2221 C2221 
a, b, c (Å) 67.2, 128.1, 192.9 66.6, 127.3, 190.8 
α, β, γ (deg) 90.00, 90.00, 90.00 90.00, 90.00, 90.00 
Resolution (Å) 2.50 – 29.8 2.30 – 29.5 
RMerge 0.090 (0.027) 0.084 (0.40) 
Completeness (%) 99.6 (98) 99.8 (99.0) 
I/σ 23.3 (3.3) 15.1 (2.1) 
Redundancy 14.7 (14.7) 8.0 (7.7) 




Resolution (Å) 2.70 - 29.164 2.30 – 29.5 
Rwork/Rfree (%) 22.09/29.86 22.71/28.54 
# of Atoms   
Ligand 205 137 
Water 73 56 
Protein 5425 5456 
B-Factors   
Ligand 75.3 97.5 
Water 48.48 81.1 
Protein 75.59 101.6 
RMSD   
Bond length (Å) 0.010 0.009 
Bond angle (deg) 1.427 2.296 
 
Table 1 // Crystallographic statistics of complexes of clade C1086 and clade A/E93TH057 gp120 bound to NBD-
derivatives and Zenobia fragment screening hits. Numbers in parentheses represent statistics for data contained in 












Small Molecule Synthesis (Prepared by David Jones, Jongwoo Park and Joel Courter of the 




 All reactions were conducted in oven-dried glassware under an inert atmosphere of 
nitrogen or argon, unless otherwise stated. All solvents were reagent or high performance liquid 
chromatography (HPLC) grade. Anhydrous CH2Cl2 and THF were obtained from the Pure 
SolveTM PS-400 system under an argon atmosphere. All reagents were purchased from 
commercially available sources and used as received. Reactions were magnetically stirred under 
a nitrogen atmosphere, unless otherwise noted and reactions were monitored by either thin layer 
chromatography (TLC) with 0.25 mm E. Merck pre-coated silica gel plates or analytical high 
performance liquid chromatography (HPLC). Yields refer to chromatographically and 
spectroscopically pure compounds. Optical rotations were measured on a JASCO P-2000 
polarimeter. Proton and carbon-13 NMR spectra were recorded on a Bruker AM-500 at 305 K, 
unless otherwise noted. Chemical shifts are reported relative to chloroform (δ 7.26), methanol (δ 
3.31), or dimethyl sulfoxide (δ 2.50) for 1H NMR and either chloroform (δ 77.0), methanol (δ 
49.2), or dimethyl sulfoxide (δ 39.4). High-resolution mass spectra (HRMS) were recorded at the 
University of Pennsylvania Mass Spectroscopy Service Center on either a VG Micromass 
70/70H or VG ZAB-E spectrometer. Analytical HPLC was preformed with a Waters HPLC-MS 
system, consisting of a 515 pump and Sunfire C18 reverse phase column (20 µL injection 
volume, 5 µm packing material, 4.5 x 50 mm column dimensions) with detection accomplished 
by a Micromass ZQ mass spectrometer and 2996 PDA detector. Preparative scale HPLC was 
preformed with a Gilson 333/334 preparative pump system equipped with a 5 mL injection loop, 
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Sunfire C18 OBD column (5  µm packing material, 19 x 100 mm column dimensions) equipped 
with a UV-Vis dual wavelength (210 and 254 nm) detector and 215 liquid handling module. 
Solvent systems employed were based on the following buffers: Buffer A: H2O containing 
0.05% formic acid; Buffer B: MeCN containing 0.05% formic acid. Analytical chiral SFC was 
performed with a JASCO system, equipped with a Chiralpak IC or Chiralcel OD-H column, and 
a photodiode array detector (200-648 nm). The purity of new compounds was judged by NMR 





(±)-3,4-Benzo-cis-6-azabicyclo[3.2.0]heptane-7-one [(±)-2].1 To a solution of indene (1) (3.62 
g, 31.4 mmol) in ether (60 mL) stirring at room temperature was added chlorosulfonyl isocyanate 
(3.00 mL, 34.5 mmol) in ether (40 mL). The solution was allowed to stir for 2 h at room 
temperature, at which time, an additional 1.0 mL (11.5 mmol) of neat isocyanate was added and 
the mixture stirred an additional hour. To the mixture was added 150 mL of hexane and the 
reaction mixture was stirred vigorously. The ppt was allowed to settle, and the solvent was 
gently decanted while retaining an inert atmosphere in the reaction vessel. The solid was then 
suspended in ether (100 mL) and to the heterogeneous mixture was added 5 mL of 0.2 M 
aqueous Na2SO3 dropwise (the reaction mixture was kept basic by the occasional dropwise 
addition of 10% KOH solution). After completing the addition of Na2SO3, 100 mL of hexane 
was added and the heterogeneous solution was filtered. The filtrate was washed with additional 
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hexane and the mother liquor was concentrated to remove ether and filtered again. The crude 
product was dissolved in a minimal amount of hot methanol and EtOAc was added until the 
solution remained slightly cloudy. The solution was then cooled and the precipitate collected to 
provide 2.05 g (41%) of (±)-2 as a white solid.i  
 
 
(±)-N-Boc-3,4-benzo-cis-6-azabicyclo[3.2.0]heptanes-7-one [(±)-3]. To a solution of (±)-2 (409 
mg, 2.57 mmol) in MeCN (10 mL) at 0 °C, was added DMAP (78 mg, 0.64 mmol), followed by 
Boc2O (1.12 g, 5.14 mmol). The solution was warmed to rt and stirred for 1 h. The mixture was 
diluted with dichloromethane, washed with a sat. NaHCO3 solution, and washed with a sat. brine 
solution. The organic layer was then dried with anhydrous MgSO4 and concentrated. The crude 
mixture was purified by silica gel column chromatography using 10%  30% EtOAc/hexane to 






(±)-N-Boc-cis-(2-(hydroxymethyl)indanyl-1-amine  [(±)-4]. To a solution of (±)-3 (581 mg, 
2.25 mmol) in THF (10 mL) at 0°C was added solid LiAlH4 (298 mg, 7.86 mmol) portionwise. 
The reaction mixture was then warmed to rt and stirred overnight. The reaction was then 
!!
133!
quenched with the dropwise addition of 0.3 mL H2O, after 5 minutes, this was followed by 0.3 
mL of 15% aqueous NaOH, and then after another 5 minutes, an additional 0.9 mL of H2O was 
added. The heterogeneous mixture was stirred until the solid aluminum salts became white and 
the precipitate was filtered off. The remaining solution was then concentrated and the residue 
purified by silica gel column chromatography using 20%  50% EtOAc/hexane to provide 463 
mg (78%) of (±)-4. 1H NMR (500 MHz, DMSO-d6): d ppm = 7.38 (d, J = 6.9 Hz, 1H), 7.19 - 
7.28 (m, 3H), 5.12 (dd, J = 6.9, 6.7 Hz, 1H), 4.56 (d, J = 6.9 Hz, 1H), 3.75 - 3.85 (m, 1H), 3.65 - 
3.75 (m, 2H), 2.84 (dd, J = 15.0 Hz, 7.3 Hz, 1H), 2.70 - 2.80 (m, 1H), 2.59 (dd, J = 15.0, 9.7 Hz, 
1H), 1.47 (s, 9H); HRMS (ES+) m/z 286.1422 ([M+Na]+; calcd for C15H21NO3Na: 286.1419). 
 
 
N1-(4-Chloro-3-fluorophenyl)-N2-(cis-2-(hydroxymethyl)-indan-1-yl)oxalamide [(±)-7]. To a 
solution of (±)-4 (463 mg, 1.76 mmol) in CH2Cl2 (5 mL) at 0°C was added TFA (2 mL). The 
reaction mixture was warmed to rt and stirred for 45 min. The solution was then cooled back to 
0°C and the quenched with NaOH until the pH of the aqueous layer was 13–14. The aqueous 
layer was extracted with CH2Cl2 (8 x 5 mL), the combined organics were then dried with 
anhydrous Na2SO4 and concentrated to afford the crude amino alcohol (±)-5. The crude amine 
(±)-5 was immediately dissolved in EtOH (5 mL) and the solution was transferred into a vial 
containing oxalate 6, the vial was then sealed and the solution was heated to 150°C in a 
microwave reactor for 1 hr. Upon cooling to rt, a precipitate formed in the reaction vessel. The 
ppt was filtered and washed with small portions of cold CH2Cl2 to provide 455 mg of (±)-7 as a 
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white solid. 1H NMR (500 MHz, DMSO-d6) d ppm = 11.08 (br. s., 1H), 9.22 (d, J = 8.7 Hz, 1H), 
7.95 (dd, J = 11.8, 2.3 Hz, 1H), 7.73 (dd, J = 8.9, 1.8 Hz, 1H), 7.57 (d, J = 17.2 Hz, 1H), 7.20 - 
7.28 (m, 3H), 7.13 - 7.20 (m, 1H), 5.45 (t, J = 8.2 Hz, 1H), 4.81 (t, J = 4.8 Hz, 1H), 3.51 – 3.60 





N1-(4-Chloro-3-fluorophenyl)-N2-(cis-2-formylindan-1-yl)oxalamide [(±)-8]. To a solution of 
alcohol (±)-7 (140 mg, 0.38 mmol) in CH2Cl2/DMSO (1:1, 2 mL) at 0°C was added i-Pr2NEt 
(0.40 mL, 2.32 mmol), followed by SO3•Pyr (363 mg, 2.28 mmol). The reaction mixture was 
stirred at 0°C for 45 min, and then quenched by the addition of a sat. solution of NaHCO3 (3 
mL). The aqueous layer was extracted with CH2Cl2 (3 x 3 mL), and the combined organic layers 
washed with brine and dried with anhydrous Na2SO4. After concentration of the organic layers, 
the crude material was then purified by silica gel chromatography using 20%  25% 
EtOAc/hexane to afford 122 mg (89%) of pure (±)-8 as an inconsequential mixture of ~5.5:1 
mixture of epimers. 1H NMRmajor (500 MHz, DMSO-d6): d ppm =  11.03 (s, 1H), 9.68 (d, J = 
1.6 Hz, 1H), 9.46 (d, J = 8.9 Hz, 1H), 7.92 (dd, J = 11.8, 2.2 Hz, 1H), 7.72 (d, J = 9.3 Hz, 1H), 
7.57 (t, J = 8.7 Hz, 1H), 7.19 - 7.33 (m, 4H), 5.73 (t, J = 8.7 Hz, 1H), 3.56 - 3.62 (m, 1H), 3.49 







(±)-9]. To a solution of aldehyde (±)-8 (35 mg, 0.1 mmol) in MeOH/CH2Cl2 (1:1, 3 mL) was 
added to ammonium trifluoroacetate (131 mg, 1.0 mmol). The solution was stirred at rt 
overnight. The solvent was then evaporated and the residual solvents were then removed via 
azeotrope with toluene (~10 mL). The dry solid was then dissolved in THF (5 mL) and the 
solution stirred for 1 h, at which time, NaBH(OAc)3 (25 mg, 0.12 mmol) was added in one 
portion. The reaction mixture was stirred for 4 h at rt, and then concentrated directly onto silica 
gel. The crude mixture was purified by silica gel chromatography using 50:1  20:1  10:1 
CH2Cl2/MeOH to afford 18 mg (50%) of DMJ-II-118B (±)-9 as a white solid. 1H NMR (500 
MHz, DMSO-d6): d ppm =  9.39 (br s, 1H), 7.97 (dd, J = 11.8, 2.2 Hz, 1H), 7.75 (d, J = 9.0 Hz, 
1H), 7.59 (t, J = 8.7 Hz, 1H), 7.14 - 7.27 (m, 4H), 5.20 (d, J = 6.5 Hz, 1H), 3.10 - 3.16 (m, 1H), 
2.96 - 3.02 (m, 2H), 2.71-2.74 (m, 2H); 13C NMR (125 MHz, DMSO-d6): d ppm = 160.1, 158.8, 
156.8 (d, JCF = 243 Hz), 142.1, 141.2, 138.3 (d, JCF = 10 Hz), 130.6, 127.7, 126.6, 124.5, 123.5, 
117.3 (d, JCF = 3.3 Hz), 114.3 (d, JCF = 18 Hz), 108.4 (d, JCF = 26 Hz), 57.5, 45.7, 41.8, 34.3; 






salt [DMJ-II-121, (±)-11]. To a solution of amine (±)-9 (15 mg, 0.04 mmol) in DMF (1 mL) 
was added i-Pr2NEt (30 µL, followed by carbamidine 10 (12 mg, 0.08 mmol). The mixture was 
then heated to 65°C for 2 h. The reaction mixture was then cooled to rt and diluted with of 
MeCN/H2O (2:1, 1.2 mL) and the product purified via HPLC to provide 3.7 mg (21%) of the 
formate salt (±)-DMJ-II-121 [(±)-11] as a white solid. 1H NMR (500 MHz, DMSO-d6) d ppm = 
11.06 (br s, 1H), 9.41 (d, J = 8.8 Hz, 1H), 8.36 (s, 1H), 8.05 (br s, 1H), 7.97 (dd, J = 11.8, 2.2 
Hz, 1H), 7.75 (d, J = 7.5 Hz, 1H), 7.59 (t, J = 8.7 Hz, 1H), 7.37 (br s, 3H), 7.14 - 7.27 (m, 4H), 
5.18 (t, J = 8.4 Hz, 1H), 3.30 - 3.41 (m, 2H), 3.11 - 3.17 (m, 2H), 2.79 - 2.84 (m, 1H), 2.65 - 2.71 
(m, 1H); HRMS (ES+) m/z 404.1281 ([M+H]+; calcd for C19H20N5O2FCl: 404.1290). The 




(1R,2R)-1-Amino-2,3-dihydro-1H-indene-2-carboxylic acid [(1R,2R)-10]. Racemic (±)-2 (530 
mg, 3.32 mmol) was suspended in i-Pr2O (50 mL). After addition of lipolase (1.0 g, lipase B 
from Candida Antarctica on styrene) and H2O (60 µL, 3.32 mmol), the mixture was shaken in a 
water bath at 60 oC. The reaction was monitored by chiral SFC (Chiralcel OD-H, 20% (0.5% 
NEt3/MeOH)/CO2, 254 nm, 4 mL/min, 12 MPa; (1S,2S)-isomer: tr = 1.8 min and (1R,2R)-
isomer: tr = 2.5 min), and was stopped when the ee of β-lactam (1S,2S)-2 reached 99%. The 
reaction mixture was filtered off to collect enzyme and amino acid and washed by MeOH several 
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times. The filtrate was evaporated under reduced pressure, and the residue was recrystallized 
from MeOH/EtOAc to afford β-lactam (1S,2S)-2 (250 mg, 47%, 99% ee). The filtered enzyme 
and amino acid were washed with hot H2O, and the H2O was evaporated under reduced pressure. 
The residue was washed with small amount of MeOH to afford β-amino acid (1R,2R)-12 (175 
mg, 30%, 99% ee) as a white solid.iii  
 
 
(1R,2R)-(1-Amino-2,3-dihydro-1H-inden-2-yl)methanol [(1R,2R)-5]. To a solution of 
(1R,2R)-12 (121 mg, 0.68 mmol) in THF (5 mL) at 0 °C, was carefully added LiAlH4 (104 mg, 
2.74 mmol). The solution was heated to reflux and stirred overnight. The reaction mixture was 
cooled to 0 °C, then quenched with the dropwise addition of 0.10 mL H2O, followed by 0.10 mL 
of 15% aqueous NaOH, an additional 0.20 mL of H2O was added. The heterogeneous mixture 
was stirred until the solid aluminum salt became white and the precipitate was filtered off. The 
resulting solution was concentrated to give 78 mg (70%) of (1R,2R)-5 as a pale yellow solid. 






yl)oxalamide [(1R,2R)-7]. A solution of amino alcohol (1R,2R)-5 (105 mg, 0.64 mmol) in EtOH 
(1.5 mL) was transferred into a vial containing oxalate 6 (157 mg, 0.64 mmol), the vial was then 
sealed and the mixture was heated to 150°C in a microwave reactor for 1 h. Upon cooling to rt, a 
precipitate formed in the reaction vessel. The reaction mixture was purified by silica gel column 
chromatography using 20%  100% EtOAc/Hexanes to give 171 mg (73%) of (1R,2R)-7 as a 




yl)oxalamide [(1R,2S)-13]. To a solution of alcohol (1R,2R)-7 (115 mg, 0.32 mmol) in 
CH2Cl2/DMSO (1:1, 4 mL) at 0°C was added i-Pr2NEt (0.34 mL, 1.95 mmol), followed by 
SO3•Pyr (303 mg, 1.90 mmol). The reaction mixture was stirred at 0°C for 1 h, and then 
quenched by the addition of saturated aqueous NaHCO3. The aqueous layer was extracted with 
CH2Cl2 (3 x 5 mL), and the combined organic layer washed with brine and dried over anhydrous 
Na2SO4. After concentration of the organic layer, the residue was purified by silica gel column 
chromatography using 10%  100% EtOAc/hexane to give the desired aldehyde (see 1H NMR 
data above). To a solution of the resulting aldehyde in 1:1 MeOH/CH2Cl2 (6 mL) was added 
ammonium trifluoroacetate (207 mg, 1.58 mmol). The solution was stirred at rt overnight, then 
the reaction mixture was evaporated to remove solvent, the crude residue was dissolved in ethyl 
acetate, washed with water, dried with Na2SO4, and concentrated. The 1H NMR of crude 
aldehyde indicated that the ratio of epimers was ~8:1 (α:β) [1H NMRmajor (500 MHz, DMSO-d6) 
d ppm 11.07 (s, 1H), 9.83 (d, J = 2.0 Hz, 1H), 9.58 (d, J = 8.9 Hz, 1H), 7.95 (dd, J = 9.9, 2.3 Hz, 
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1H), 7.74 (d, J = 9.3 Hz, 1H), 7.58 (t, J = 8.8 Hz, 1H), 7.16 - 7.32 (m, 4H), 5.74 (t, J=7.2 Hz, 
1H), 3.50 - 3.57 (m, 1H), 3.21 - 3.28 (m, 1H), 3.13 - 3.19 (m, 1H)]. The partially epimerized 
aldehyde was then dissolved in EtOH, and NaBH4 was added. After stirring overnight, the 
reaction mixture was quenched with H2O. The mixture was diluted with EtOAc, and washed 
with H2O and brine. The organic layer was dried over anhydrous Na2SO4, and the residue was 
washed with a CH2Cl2/hexane mixture (1:1) to give 86 mg (74%) of (1R,2S)-13 as a white solid. 
1H NMR (500 MHz, DMSO-d6) d ppm = 11.06 (s, 1H), 7.96 (dd, J = 11.9, 2.2 Hz, 1H), 7.71 - 
7.77 (m, 1H), 7.51 - 7.61 (m, 1H), 7.11 - 7.27 (m, 4H), 5.23 (t, J = 8.3 Hz, 1H), 4.69 (t, J = 5.1 
Hz, 1H), 3.48 - 3.60 (m, 2H), 3.01 - 3.09 (m, 1H), 2.65 - 2.77 (m, 2H); HRMS (ESI-) m/z 






yl)methyl methanesulfonate [(1R,2S)-14]. To a mixture of alcohol (1R,2S)-13 (75 mg, 0.21 
mmol) and Et3N (0.11 mL, 0.79 mmol) in DCM (5 mL) at 0°C was added MsCl (48 µL, 0.62 
mmol). After stirring overnight, the reaction mixture was concentrated. The residue was diluted 
with EtOAc and then washed with 1 N HCl, sat. NaHCO3, and brine. The organic layer was 
dried over anhydrous Na2SO4, concentrated under reduced pressure, and the residue was purified 
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by silica gel column chromatography using 20%  100% EtOAc/hexane to give 50 mg (55%) of 





oxalamide [(1R,2R)-15]. To a solution of (1R,2S)-14 (50 mg, 0.11 mmol) in DMSO (1 mL) at 
rt, was added NaN3 (15 mg, 0.23 mmol). The solution was heated to 70°C and stirred for 3 h at 
this temperature. The reaction mixture was diluted with EtOAc, and washed with H2O and brine. 
The organic layer was dried over anhydrous Na2SO4, concentrated under reduced pressure, and 
the residue was purified by silica gel column chromatography using 10%  33% EtOAc/hexane 






oxalamide [(1R,2R)-9]. To a solution of (1R,2R)-15 (31 mg, 0.080 mmol) in EtOAc (4 mL) at 
rt, was added Pd-C (8 mg). The solution was stirred for 2.5 h at rt under H2 balloon. The reaction 
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mixture was filtered through celite, and the solvent was removed under reduced pressure to give 





(1R,2R)-DMJ-II-121 [(1R,2R)-11]. To a solution of amine (1R,2R)-9 (25 mg, 0.080 mmol) in 
DMF (0.5 mL) was added i-Pr2NEt (56 µL, 0.32 mmol), followed by carbamidine 10 (23 mg, 
0.16 mmol). The mixture was then heated to 65°C for 3 h, then cooled to rt and diluted with of 
CH3CN and the product purified via HPLC to afford 27 mg (75%) of the formate salt of (1R,2R)-
DMJ-II-121 as a white solid. (See NMR and HRMS data above), [α] = +45.05 (c 0.28, MeOH); 
99% ee by SFC (Chiralpak IC, 40% (0.5% NEt3/MeOH)/CO2, 254 nm, 4 mL/min, 12 MPa); 
(1R,2R)-isomer: tr = 3.1 min (major) and (1S,2S)-isomer: tr = 4.2 min (minor). 
 
 
N1-(4-Chloro-3-fluorophenyl)-N2-(5-azaspiro[3.5]nonan-8-yl)oxalamide [(±)-17]. To a 
solution of amine 16 (114 mg, 0.81 mmol) in 2 mL of EtOH in a 5 mL microwave reaction 
vessel was added oxalate 6 (200 mg, 0.81 mmol). The reaction vessel was then sealed and heated 
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to 150°C for one hr in a microwave reactor. After cooling to room temperature, the solid 
precipitate was collected via vacuum filtration and washed with cold hexanes. The product was 
then dried to give 197 mg (71% yield) of (±)-17. 1H NMR (500 MHz, DMSO-d6): d ppm = 
10.96 (s, 1H), 8.91 (d, J = 7.0 Hz, 1H), 7.93 (dd, J = 12.0, 2.5 Hz, 1H), 7.71 (m, 1H), 7.58 (t, J = 
8.5 Hz, 1H), 3.74 (m, 1H), 2.72 (m, 1H), 2.55 (m, 1H), 2.1 (br s, 1H), 1.95 (m, 1H), 1.90-1.65 













IC50 Viral Assays (performed by Navid Madani of the Joseph Sodroksi Lab at the Dana-
Farber Cancer Institute) 
 
Production of recombinant luciferase expressing HIV-1 
293T human embryonic kidney cells were grown in Dulbecco’s modified Eagle medium 
(DMEM) from Invitrogen containing 10% fetal bovine serum (Sigma) and 100 µg/mL 
penicillin−streptomycin (Meditech) at 37°C and 5% CO2.  293 T cells were then cotransfected 
using the Effectene transfection reagent (Qiagen) with plasmids expressing: the 
pCMVΔP1ΔenvpA HIV-1 Gag-Pol packaging construct, mutant HIV-1YU-2 envelope 
glycoproteins or the wild type or the amphotropic murine leukemia virus (A-MLV) glycoprotein 
as a control, and a vector expressing the firefly luciferase at a 1:1:3 µg DNA ratio. A rev-
expressing plasmid was added to the production of virus pseudo-typed with A-MLV to ensure 
the expression of HIV-1 from the packaging plasmid. The viruses were designed unable to 
replicate and appropriate for single round use.  Filtered through a 0.45 µm sterile membrane, the 
viruses were then aliquoted and frozen at -80°C after 24 to 30 hours after transfection. The viral 
reverse transcriptase activities were measured as described previously (Rho et al, 1981). 
 
Assay of virus infectivity and small molecular inhibitor sensitivity  
In order to measure the ability of a small molecule to prevent infection by HIV-1, target 
cells were used expressing the two necessary receptors for viral entry: CD4 along with either of 
the coreceptors CXCR4 or CCR5.  Drug candidate compounds were dissolved with dimethyl 
sulfoxide (DMSO) to a concentration of 10 mM and stored at -20°C. Before use, drug 
compounds were diluted in DMEM.  Cf2Th target cells expressing CD4+/CCR5+ (primary 
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YU2-isolate) or CD4+/CXCR4+ (laboratory-adapted HXBc2-isolate) were grown as previously 
described for 293T cells but supplemented with the antibiotic 0.20 mg/mL hygromycin B 
(Roche) and the selective agent 0.4 mg/mL G418 (Invitrogen). Grown Cf2Th CD4+/CCR5+ and 
Cf2Th CD4+/CXCR4+ target cells were seeded into 96-well luminometer-compatible tissue 
culture plates (Perkin Elmer), at a density of 6 x 103 cells per well and incubated for 24 hours in 
serum-free DMEM. On the day of the infection with the target cells still incubating, 1-100 µM of 
the drug of interest was added to recombinant viruses (10,000 reverse transcriptase units) and 
incubated at 37°C for 30min in a final volume of 50 µL. After the serum-free DMEM was 
removed, the target cells were incubated at 37°C in the recombinant virus-drug mix for 2-4 
hours. Upon completion of this incubation phase, complete medium was added to make a final 
volume of 150 µL and incubated for a further 48hrs at 37°C. From each well, the medium was 
removed and the target cells lysed with 30 µL of passive lysis buffer (Promega) using 3 freeze-
thaw cycles. 100 L of luciferin buffer (1 mM dithiothreitol, 15 mM magnesium sulfate, 15 mM 
potassium phosphate buffer [pH 7.8], 1 mM ATP) and 50 µL of 1 mM D-luciferin potassium salt 
(BD Pharmingen) was added to each well and its luciferase activity was measured by an EG&G 
Berthold microplate luminometer LB 96V. 
 
Thermodynamic analysis (performed by Arne Schon of John Hopkins University) 
Isothermal titration calorimetric experiments were performed using a high-precision VP-
ITC titration calorimetric system from MicroCal Inc. (Northampton, MA).  Binding to full length 
YU2 gp120 was studied in experiments where the calorimetric cell, containing 2 µM gp120 in 
PBS, pH 7.4 (Roche Diagnostics GmbH), with 2 % DMSO, was titrated with inhibitor dissolved 
at a concentration of 40 – 80 µM in the same buffer with 2 % DMSO.  All titrations were 
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performed by adding the titrant in steps of 10 µL.  The solutions were properly degassed to avoid 
any formation of bubbles in the calorimeter during stirring.  The heat evolved upon each 
injection of inhibitor was obtained from the integral of the calorimetric signal.  The heat 
associated with binding to gp120 in the cell was obtained by subtracting the heat of dilution from 
the heat of reaction.  The individual heats were plotted against the molar ratio and the enthalpy 
























i Procedure adapted from: Fulop, F.; Palko, M.; Kaman, J.; Lazar, L.; Sillanpaa, R. Tetrahedron: 
Asymmetry 2000, 11, 4179. Spectra are consistent with literature report.  
ii Spectra consistent with literature report: Fulop, F.; Forro, E.; Toth, G. K. Org. Lett. 2004, 6, 4239. 
iii Procedure adapted from: Forró, E.; Fülöp, F. Chem. Eur. J. 2006, 12, 2587. Spectra consistent with 






Strategies for future development of small 
molecule gp120/CD4 inhibitors 
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 Through the use of x-ray crystal structures, we increased the potency of our NBD-
derivatives more than 30 fold from the original NBD-556 to the our most potent small 
molecular gp120/CD4 binding inhibitor to date: DMJ-II-121-R,R.  Equal to the 
achievement in improved Kd binding capability is the ability for DMJ-II-121-R,R to bind 
at the PHE43CD4 pocket with a Kd of 0.11 µM without activating gp120 into a 
coreceptor-ready state.  No matter how well a drug blocks the natural ligand CD4 from 
binding to gp120, it would be not only useless but detrimental if it still agonistically 
induces gp120 to bind to CCR5 or CXCR4.  Although we have not yet achieved a small 
molecule inhibitor that binds to PHE43CD4 cavity at a subnanomolar range, we do have a 
working motif that binds to the cavity without agonistic effects.  In essence, we now have 
a scaffold that is known to lock itself to the PHE43CD4 cavity that will allow chemical 
elaborations off this anchor piece for the next generation of NBD-derivatives and 
interactions with the surrounding residues around the binding site. 
 A recent study of CD4-gp120 interaction performed an alanine scanning 
mutagenesis on CD4 residues that make contact with the surface of gp120 during binding 
and used isothermal calorimetry to determine which residue interactions contribute to 
binding and which to the activation of gp120. The characteristics found in the CD4 
residues were then correlated with the particular gp120 residues that the CD4 moieties 
contact during protein-protein interaction.  They discovered a patch of gp120 residues 
near the β23 and loop D that contribute strongly to the affinity of CD4 binding but not to 
the activation of gp120 (Liu et al, 2013).  Interactions with this patch would be a 
promising target to improve drug affinity of a small molecule inhibitor of gp120 binding.  
In relation to a compound bound to the PHE43CD4 site, the target patch is not too far out 
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of reach for the creation of a compound that takes advantage of both sites.  Figure 1 
shows the patch of affinity contributing gp120 residues in relation to DMJ-II-121-R,R.  
Chemical elaboration off the indane ring will need to reach across a gap of 7.8 to 9.0 
angstroms to interact with the closest moieties in the patch.  Ideally a chemical addition 
would reach this patch while still maintaining the methylguanidinium hydrogen bond 




Figure 1 // gp120 residues that contribute to affinity but not activation of gp120 in relation to DMJ-
II-121-R,R. A. Surface representation of gp120 in sky blue with residues that contribute to affinity of CD4 
binding highlighted in light grey. B. Close up of DMJ-II-121-R,R and residues contributing to CD4 affinity 
but not gp120 activation represented as sticks with light grey carbons.  DMJ-II-121-R,R in both is 
represented as a stick diagram with yellow carbons.  Nitrogens = Blue, Oxygen = Red. Data based on (Liu 
et al, 2013). 
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 The chemical elaboration to improve the binding capability of DMJ-II-121-R,R 
would be more ideal off the benzene ring of the indane.  Our collaborators have already 
tried to elaborate the methylguanidinium by extending its reach with an extra carbon.  
Figure 2 shows that the resulting dimethylguanidinium has poorer binding affinity (0.34 
µM) and viral inhibition (28.2 µM) compared to those of DMJ-II-121-R,R (0.11 µM and 
2.3 µM, respectively).  Due to this observation, elaborating off the benzene moiety of the 
indane will open doors for new interactions with the neighboring residues of the 
PHE43CD4 cavity while allowing the preservation of the methylguanidinium to maintain 
the MET426 interaction as seen in the DMJ-II-121-R,R structure. 
 
Figure 2 // Extension of the guanidinium reduces potency of DMJ-II-121. A. DMJ-II-121-R,R with 
methylguanidinium.  B. New design incorporating a dimethylguanidinium. Potency is reduced. The 
isothermal calorimetry experiment to determine affinity Kd was performed at 25°C. Compound 
concentrations that inhibit 50% of viral infection were calculated using 10,000 RT units of wild-type YU2 
HIV-1 expressing luciferase to infect Cf2TH-CD4/CCR5 cells with increasing concentration of the 





Figure 3 // Simulation of possible interactions between affinity contributing residues and new designs 
using DMJ-II-121-R,R as a scaffold. Two new designs use DMJ-II-121-R,R as a scaffold incorporating a 2'(methylamino)ethanimidamide!that branches off at different points on the indane.  The design allows for 
the potential of preserving all critical interactions seen previously in the DMJ-II-121-R,R structure and 
allows for new interactions with affinity contributing residues highlighted in an alanine scanning study (Liu 
et al, 2013). One of the designs allow for a possible direct hydrogen bond with GLY472gp120 previously 




Besides designing new interactions with the neighboring residues of the 
PHE43gp120 cavity, we can still capitalize on some unexploited interactions available on 
the inside of the pocket. Examining the interior of the PHE43CD4 cavity around Region I 
of DMJ-II-121-R,R, there are still areas of the cavity not fully occupied by the 
halogenated phenyl ring.  The perspective of Figure 4A looks up at the “roof” of the 
interior cavity showing that the region above the para-chlorine as well as the 
unhalogenated meta-position on the phenyl ring are still available for interaction. A water 
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channel near the unhalogenated meta- position has also not been utilized so far by the 
NBD-derivatives (Figure 4B).  The crystal structures in this work show examples of van 
der Waals interactions with these water molecules filling the channel.  However, a 
hydrogen bond or even a chemical elaboration that extends into this channel could 
provide critical interactions with α1 and β2 residues of the inner domain.  The hindrance 
to filling out the cavity “roof” and waterchannels are the limitations of chemical 
elaboration without changing the motifs that are already critical in the binding of DMJ-II-
121-R,R. 
!
Figure 4 // Areas of the PHE43CD4 cavity available for van der Waals interaction by DMJ-II-121-R,R. 
A. Bottom perspective of the cavity roof.  Areas involved in van der Waals contacts by DMJ-II-121-R,R 
are highlighted in red while areas available for exploitation of chemical elaboration remain in blue. B. Top 
perspective of DMJ-II-121-R,R and the 3 water molecules that form the water channel. !
! Benzimidazole and 3-hydroxyphenylacetic acid identified in the Zenobia 
fragment library x-ray crystal screening provide two separate future strategies for 
development of PHE43CD4 binding compounds.  The novel motifs offer two different 
possible scaffolds to build a new progression of compound families distinct from the 
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NBD-derivative legacy.  Future exploration can fork off into two paths incorporating 
each fragment in the design progression.  The 3-hydroxyphenylacetic acid derivatives 
need to focus on preserving the direct hydrogen bond with GLU370 since this ionic 
interaction has not yet been exploited in any of the NBD-derivatives.  The benzimidazole 
on the other hand has no direct hydrogen bonds with the interior residues of the 
PHE43CD4 cavity--only an indirect ionic interaction with GLY473.  All of the NBD-
derivative structures show a direct hydrogen bond with GLY473. If chemical elaboration 
can add an extension off benzimidazole to displace the water molecule and make a direct 
hydrogen bond instead, the resulting compound could possible have a better binding 
capacity.   
!
Figure 5 // Benzimidazole and 3-hydroxyphenylacetic acid superimposed into clade C1086 gp120. The 
gap between the two fragments for chemical linker exploitation is 2.9 angstroms.  Both fragments are 
depicted as sticks with light grey carbons.  Nitrogens are colored blue and Oxygen red.  The sky blue 
ribbon diagram represents gp120.  Distance measured with CHIMERA (Pettersen et al, 2004). !
Attempts can be made to design a molecule that includes both fragments as well.  
As seen in Figure 5, if a chemical synthesis is devised to bridge the gap of 2.9 angstroms 
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between the benzimidazole and 3-hydroxyphenylacetic acid, the resulting compound can 
take advantage of both fragments interaction with the cavity.   
Ultimately, the crystal structures of NBD-derivatives along with the crucial 
structure activity relationship data from binding and viral inhibition/specificity assays 
have guided chemical synthesis to design our most potent small molecular entry inhibitor 
to this date, DMJ-II-121-R,R.  With the information from this work we can use the 
identified critical interactions between the DMJ-II-121-R,R and the PHE43CD4 cavity to 
guide the next elaboration round of novel compounds alongside the possibilities of  new 
families of compounds that can be derived from the positive leads in the crystallographic 
fragment screen.  With this work, we are stepping in the right direction and closer toward 
the subnanomolar binding affinity of an ideal gp120-CD4 HIV-1 entry inhibitor.  
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